Patent Grant
8932221
As medical technology advances, many diagnostic and therapeutic activities are carried out with increasingly small implantable medical or ingestible medical devices. Implantable and ingestible medical devices can be configured to perform a variety of different functions, including but not limited to: diagnostic functions, e.g., where the devices include one or more sensors; therapeutic functions, e.g., where the devices enable therapeutic action, such as delivery of electrical pulse, delivery of a pharmaceutically active agent; etc.
With implantable and ingestible medical and related technologies, there is always a desire to make the devices smaller, e.g., to provide for increased ease of use, etc. To decrease size, individual components of the devices must be designed with a reduced overall physical size, and yet maintain functionality.
One type of component that is present in many implantable and ingestible devices is a signal transmitter. There is continued interest in the development of signal transmitters for in-body devices that have adequate and reliable functionality and are physiologically compatible such that they can be employed with in-body devices, such as implantable and ingestible devices.
Multi-directional transmitters for in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body multi-direction transmitters of the invention include signal transmitters configured to transmit an identifying signal in at least two different directions in an x-y plane. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.
The multi-direction transmitters of the invention enable robust detection of a signal emitted by an in-body device, since the transmitter of the present invention includes a multi-directional transmitter capability, thereby enhancing the likelihood that a signal will be emitted in a direction that will be detected by a receiver, despite the particular position of the device and transmitter relative to the receiver when the signal is emitted.
Embodiments of the invention include ingestible event marker compositions having an identifier and a pharmaceutically acceptable carrier. The identifier is characterized by being activated upon contact with a target site fluid present at a target site. Aspects of the identifier include the presence of a multi-directional transmitter. Upon activation, a signal broadcasted from the identifier may be received by another device, e.g., a receiver, either inside or near the body, which may then record that the pharmaceutical composition has in fact reached the target site.
Multi-directional transmitters for in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body multi-direction transmitters of the invention include signal transmitters configured to transmit an identifying signal in at least two different directions in an x-y plane. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.
In further describing the invention in greater detail, embodiments of the multi-direction transmitters and in-body devices that include the same are reviewed first, followed by a discussion of systems having devices that include the in-body devices, and methods of using such devices and systems. Also reviewed in greater detail below are kits that include the in-body devices of the invention.
In-Body Devices Having Multi-Directional Transmitters
As summarized above, the invention provides in-body devices having multi-directional transmitters. An in-body device is a device that is configured to be used inside of a living body. Examples of in-body devices include, but are not limited to: implantable devices, e.g., implantable therapeutic devices, such as but not limited to stents, drug delivery devices, orthopedic implants, etc., implantable diagnostic devices, e.g., sensors, biomarker recorders, etc; and ingestible devices, e.g., ingestible event markers (e.g., as described in greater detail below), etc.
One type of in-body device in which the transmitters of the invention find use is an ingestible event marker. For ease of description, the in-body devices of the invention will now be further described in terms of embodiments where the transmitter is part of an identifier of an ingestible event marker. However, as indicated above, the transmitters of the invention find use in devices other than ingestible event markers, and therefore transmitters of the invention are not limited to those configured for use in ingestible event markers (IEM).
The identifier of the IEM compositions is one that generates (i.e., emits) a detectable signal upon contact of the identifier with a target physiological site. The identifiers of the present compositions may vary depending on the particular embodiment and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach. As such, an ingestible event marker may comprise an identifier that emits a signal when activated at a target site, e.g. when it contacts a target body (i.e., physiological) site. The identifier may be any component or device that is capable of providing a detectable signal following activation, e.g., upon contact with the target site. The identifier therefore comprises a signal generation element, e.g. a multi-directional transmitter. In certain embodiments, the identifier emits a signal once the composition comes into contact with a physiological target site, e.g., the stomach. Depending on the embodiment, the target physiological site or location may vary, where representative target physiological sites of interest include, but are not limited to: a location in the gastrointestinal tract, such as the mouth, esophagus, stomach, small intestine, large intestine, etc. In certain embodiments, the identifier is configured to be activated upon contact with fluid at the target site, e.g. stomach fluid, regardless of the particular composition of the target site.
Depending on the needs of a particular application, the signal obtained from the identifier may be a generic signal, e.g., a signal that merely identifies that the composition has contacted the target site, or a unique signal, e.g., a signal which in some way uniquely identifies that a particular ingestible event marker from a group or plurality of different markers in a batch has contacted a target physiological site. As such, the identifier may be one that, when employed with a batch of unit dosages, e.g., a batch of tablets, emits a signal which cannot be distinguished from the signal emitted by the identifier of any other unit dosage member of the batch. In yet other embodiments, the identifier emits a signal that uniquely identifies that particular identifier. Accordingly, in certain embodiments the identifier emits a unique signal that distinguishes one class of identifier from other types of identifiers. In certain embodiments, the identifier emits a unique signal that distinguishes that identifier from other identifiers. In certain embodiments, the identifier emits a signal that is unique, i.e., distinguishable, from a signal emitted by any other identifier ever produced, where such a signal may be viewed as a universally unique signal (e.g., analogous to a human fingerprint which is distinct from any other fingerprint of any other individual and therefore uniquely identifies an individual on a universal level). In one embodiment, the signal may either directly convey information about a given event, or provide an identifying code, which may be used to retrieve information about the event from a database, i.e., a database linking identifying codes with compositions.
The identifier may generate a variety of different types of signals, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc. Of interest in certain embodiments are the specific signals described in pending PCT application serial no. PCT/US2006/16370 filed on Apr. 28, 2006; the disclosures of various types of signals in this application being specifically incorporated herein by reference. The transmission time of the identifier may vary, where in certain embodiments the transmission time may range from about 0.1 μsec to about 48 hours or longer, e.g., from about 0.1 μsec to about 24 hours or longer, such as from about 0.1 μsec to about 4 hours or longer, such as from about 1 sec to about 4 hours, including about 1 minute to about 10 minutes. Depending on the given embodiment, the identifier may transmit a signal once or transmit a signal two or more times, such that the signal may be viewed as a redundant signal.
The identifiers may vary depending on the particular embodiment and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach. As such, the identifier may be an identifier that emits a signal when it contacts a target body (i.e., physiological) site. In addition or alternatively, the identifier may be an identifier that emits a signal when interrogated after it has been activated. Identifier components of embodiments of the invention have: (a) an activation component; and (b) a signal generation component, where the signal generation component is activated by the activation component to produce an identifying signal, e.g., as described above.
The activation component is a component that activates the signal generation element of the identifier to provide a signal, e.g., by emission or upon interrogation, following contact of the composition with a target physiological site of interest, such as the stomach. As reviewed in co-pending PCT application serial no. PCT/US2006/016370, activation of the identifier may be achieved in a number of different ways, where such approaches include, but are not limited to: battery completion, battery connection, etc. The different activation approaches disclosed in this co-pending application may be readily adapted to provide activation, as described herein, and as such are herein incorporated by reference in their entirety.
Embodiments of activation elements based on battery completion formats employ in body battery sources of the invention, where when activated the in-body batter power source includes, a cathode, an anode, and an electrolyte. In such embodiments, when the cathode and anode come into contact with stomach fluid, the stomach fluid acts as the electrolyte component of the battery, such that the added component of the stomach fluid thus completes the battery.
In certain embodiments, the battery that is employed is one that comprises two dissimilar electrochemical materials which constitute the two electrodes (e.g., anode and cathode) of the battery. When the electrode materials come in contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, i.e., a voltage, is generated between the electrodes as a result of the respective oxidation and reduction reactions occurring at the two electrodes (such that a voltaic cell or battery is produced). Accordingly, in embodiments of the invention, power sources are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated. The two dissimilar materials in an electrolyte are at different potentials. In certain of these embodiments, the in-body battery power source may be viewed as a power source that exploits electrochemical reaction in an ionic solution such as gastric fluid, blood, or other bodily fluids and some tissues.
The dissimilar materials making up the electrodes can be made of any two materials appropriate to the environment in which the identifier will be operating. The active materials are any pair of materials with different electrochemical potentials. For instance, in some embodiments where the ionic solution comprises stomach acids, electrodes may be made of a noble metal (e.g., gold, silver, platinum, palladium or the like) so that they do not corrode prematurely. Alternatively, the electrodes can be fabricated of aluminum or any other conductive material whose survival time in the applicable ionic solution is long enough to allow the identifier to perform its intended function. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.
A variety of different materials may be employed as the battery electrodes. In certain embodiments, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the signal generation element of the identifier. In certain embodiments, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain embodiments, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.
Materials and pairings of interest include, but are not limited to those reported in Table 1 below.
In certain embodiments, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery. Non-metals that may be used as doping agents in certain embodiments include, but are not limited to: sulfur, iodine and the like.
In certain embodiments, the electrode materials are cuprous iodine (CuI) or cuprous chloride (CuCl) as the cathode and magnesium (Mg) metal or magnesium alloy as the anode. Embodiments of the present invention use electrode materials that are not harmful to the human body.
Depending on the particular embodiment, the cathode and anode may be present on the same support or different supports, e.g., where two or more different supports are bonded together to produce the battery structure, e.g., as is present in a “flip-chip” embodiment. Similarly, the number of cathodes and anodes in a given battery may vary greatly depending on the embodiment, e.g., where a given embodiment may include a single battery having one anode and cathode, a single battery having multiple anodes and/or cathodes, or two or more distinct batteries each made up of one or more cathodes and/or anodes. Battery configurations of interest include, but are not limited to, those disclosed in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; PCT application serial no. PCT/US2007/022257 filed on Oct. 17, 2007 and titled “In-vivo Low Voltage Oscillator for Medical Devices”; PCT application serial no. PCT/US2007/82563 filed on Oct. 25, 2007 and titled “Controlled Activation Ingestible Identifier”; U.S. patent application Ser. No. 11/776,480 filed Jul. 11, 2007 entitled “Acoustic Pharma Informatics System”; PCT/US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; PCT/US08/53999 filed Feb. 14, 2008 and titled “In-Body Power Source Having High Surface Area Electrode,” the disclosures of which applications (and particularly battery configurations disclosed therein) are herein incorporated by reference.
In addition to the activation component, e.g., battery component, as described above, ingestible event markers of the invention include a solid support. The solid support may vary depending on the nature of the IEM. In certain embodiments, the solid support is small, e.g., where it is dimensioned to have a width ranging from about 0.01 mm to about 100 mm, e.g., from about 0.1 mm to about 20 mm, including from about 0.5 mm to about 2 mm; a length ranging from about 0.01 mm to about 100 mm, e.g., from about 0.1 mm to about 20 mm, including from about 0.5 mm to about 2 mm, and a height ranging from about 0.01 mm to about 10 mm, e.g., from about 0.05 mm to about 2 mm, including from about 0.1 mm to about 0.5 mm. The solid support element may take a variety of different configurations, such as but not limited to: a chip configuration, a cylinder configuration, a spherical configuration, a disc configuration, etc, where a particular configuration may be selected based on intended application, method of manufacture, etc. While the material from which the solid support is fabricated may vary considerably depending on the particular device for which the device is configured for use, in certain embodiments the solid support is made up of a semiconductor material, e.g., silicon.
In certain embodiments, the solid support is a semiconductor support that includes one or more circuit elements, where in certain embodiments the support is an integrated circuit. When present, integrated circuits include a number of distinct functional blocks, i.e., modules. Within a given solid support, at least some of, e.g., two or more, up to and including all of, the functional blocks, e.g., power source, processor, transmitter, etc., may be present in a single integrated circuit. By single integrated circuit is meant a single circuit structure that includes all of the different desired functional blocks for the device. In these embodiments, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain embodiments of the present invention may be hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
In addition to the activation component of the identifier, described above, identifiers of the invention also include a signal generation component. The signal generation component of the identifier element is a structure that, upon activation by the activation component, emits a detectable signal, e.g., that can be received by a receiver, e.g., as described in greater detail below. The signal generation component of certain embodiments can be any convenient device that is capable of producing a detectable signal and/or modulating transduced broadcast power, upon activation by the activation component. Detectable signals of interest include, but are not limited to: conductive signals, acoustic signals, etc. As reviewed above, the signals emitted by the signal generator may be generic or unique signals, where representative types of signals of interest include, but are not limited to: frequency shift coded signals; amplitude modulation signals; frequency modulation signals; etc.
In certain embodiments, the signal generation element includes circuitry, as developed in more detail below, which produces or generates the signal. The type of circuitry chosen may depend, at least in part, on the driving power that is supplied by the power source of the identifier. For example, where the driving power is 1.2 volts or above, standard CMOS circuitry may be employed. In other embodiments where the driving power ranges from about 0.7 to about 1.2 V, sub-threshold circuit designs may be employed. For driving powers of about 0.7 V or less, zero-threshold transistor designs may be employed.
In certain embodiments, the signal generation component includes a voltage-controlled oscillator (VCO) that can generate a digital clock signal in response to activation by the activation component. The VCO can be controlled by a digital circuit, which is assigned an address and which can control the VCO with a control voltage. This digital control circuit can be embedded onto a chip that includes the activation component and oscillator. Using amplitude modulation or phase shift keying to encode the address, an identifying signal is transmitted.
As summarized above, the signal generation component of the identifier includes a multi-directional transmitter, which may serve as a distinct transmitter component that serves to transmit the generated signal to a remote receiver, which may be internal or external to the patient, as reviewed in greater detail below. The multi-directional transmitter may also function as a signal receiver, and in certain embodiments may have both transmitter and receiver functionality, such that it is a transceiver. The transmitter may take a number of different configurations, e.g., depending on the type of signal that is generated and is to be emitted. In certain embodiments, the transmitter is made up of one or more electrodes.
Aspects of the identifier components include the multi-directional transmission capability of the identifier, such that the identifier may be viewed as a multi-directional transmission identifier. By “multi-directional” is meant two or more directions, such as three or more directions, including four or more directions, such as five or more directions, etc., where the different directions of transmission may be in a single plane or in two or more different planes, e.g., to provide for three-dimensional transmission. In certain embodiments the identifier is configured to transmit an identifying signal in at least two or three different directions in a single plane, e.g. an x-y plane. In certain embodiments, the identifier is configured is configured to transmit an identifying signal in at least two or three different directions in each of two or more different planes, e.g. two or more x-y planes. The multi-directional transmission may operate in a variety of different formats, including but not limited to electrical formats, physical formats, etc.
As summarized above, aspects of the invention include identifiers that have multi-directional signal transmission capability. Accordingly, the signal generation element is configured to provide for multi-directional signal transmission. The signal generation composition may have an integrated or a distinct transmitter component that serves to transmit the generated signal in a multi-directional manner to a remote receiver, which may be internal or external to the patient, as reviewed in greater detail below.
The transmitter component may take a number of different configurations, e.g., depending on the type of signal that is generated and is to be emitted. In certain embodiments, the transmitter component is made up of three or more transmission elements, e.g., electrodes, where the electrodes may be coupled to antenna elements, e.g., wires, where desired. In certain embodiments, the signal is transmitted either by one or two electrodes, which may or may not be part of an antenna, e.g., coupled to a wire. Accordingly, the multidirectional transmitter may be a monopole or dipole transmitter. In certain embodiments, the transmitter only requires one diode drop of power. In some embodiments, the transmitter unit uses an electric dipole or electric monopole antenna to transmit signals.
Depending on a given embodiment, the signal may or may not be modulated. For example, in certain embodiments the frequency of the signal may be held constant. In yet other embodiments, the signal may be modulated in some manner, e.g., via carrier based modulate schemes, ultra-wide band (or time domain based) modulation schemes, etc. Information can be encoded in various ways, generally by modulating (varying) some property of the transmitted signal, such as frequency, amplitude, phase, or any combination thereof. Modulation techniques known in the art may be employed.
In general, information can be transmitted using analog or digital techniques. “Analog techniques” refers generally to instances in which the modulated property is varied in different degrees, with the degree of variation being correlated to a value representing the information to be transmitted. For instance, an oscillator can be designed to operate over some range of frequencies. “Digital techniques” refers generally to instances in which the information to be transmitted is represented as a sequence of binary digits (bits), and the signal is modulated based on the bit stream. For instance, an oscillator can be designed to operate at least two different frequencies, with one frequency corresponding to bit value 0 and another frequency corresponding to bit value 1. In embodiments of the present invention, either analog techniques, digital techniques, or a combination thereof can be used to transmit information. In addition, various types of modulation may be implemented. For instance, in one embodiment, frequency modulation is used. An oscillator can be a voltage-controlled oscillator (VCO), an oscillator circuit in which the oscillation frequency depends on an applied voltage. Control logic can supply an appropriate voltage (e.g., reflecting the value of the measurement data, M), and the frequency of the signal indicates the value of the data. In another embodiment, amplitude modulation is used; for instance, the amplitude of the driving signals φ and /φ can be varied, or the positive and negative rails of the driver circuit (e.g., V+ and V−) can be varied to control the amplitude. In another embodiment, phase modulation is used. For instance, in digital signal transmission, one phase corresponds to bit value 0, an opposite phase corresponds to bit value 1, and the phase shifts represent transitions. An oscillator can include a switch circuit that either directly connects or cross-connects the driving signals φ and /φ to the inputs of a driver circuit.
In some embodiments, the transmitter may transmit a “packet” that includes a unique identifier for the identifier, which in turn is for the composition with which the identifier is associated. The unique identifier may also provide information from the remote device (e.g., the identity of the active agent (i.e., annotation information)). Other techniques for distinguishing different signals may also be used, including: operating different transmitters in different frequency bands, allowing each transmitter to be identified by its frequency and/or configuring different transmitters to transmit at different (and known) times, allowing the transmitter to be identified by when it transmits.
In certain embodiments, the signal generation component includes a voltage-controlled oscillator (VCO) that can generate a digital clock signal in response to activation by the activation component. The VCO can be controlled by a digital circuit, which is assigned an address and which can control the VCO with a control voltage. This digital control circuit can be embedded onto a chip that includes the activation component and oscillator. Using amplitude modulation or phase shift keying to encode the address, an identifying signal is transmitted.
In certain embodiments, the signal generation element includes circuitry, as developed in more detail below, which produces or generates the signal that is then transmitted in a multi-directional manner as described above. The type of circuitry chosen may depend, at least in part, on the driving power that is supplied by the power source of the identifier. For example, where the driving power is 1.2 volts or above, standard CMOS circuitry may be employed. In other embodiments where the driving power ranges from about 0.7 to about 1.2 V, sub-threshold circuit designs may be employed. For driving powers of about 0.7 V or less, zero-threshold transistor designs may be employed.
As reviewed above, the signal may vary significantly. In certain embodiment, the signal is a phase-shift-keyed signal. For example, the signal may be a 32 bit code that is phase-shift-keyed as a stream of sub-bits. In such embodiments, each sub-bit in the encoded bit stream may be implemented as a specific sequence of driver logic vectors in 16 different ways: 4 different drive patterns and 4 different data rates. For example, the code may consist of a 16-bit clock signal, a 4-bit preamble, an 8-bit payload, and a 4-bit disable sequence when all of the electrodes are off. 4 codes possible are:
In one bipolar coding scheme, the encoding scheme maps a code bit to an encoded sub-bit sequence, with the sequence repeated 16 times for a code bit 1, and the negation of the sequence repeated 16 times for a code bit 0
The encoded sub-bit stream may be modulated to the 3 electrodes in 16 different ways sequentially, which are listed below:
Monopole-2
E0/E1-2
E0/E2-2
E1/E2-2
Beacon-3
E0/E1-4
E0/E2-4
E1/E2-4
Beacon-6
E0/E1-6
E0/E2-6
E1/E2-6
Beacon-12
E0/E1-12
E0/E2-12
E1/E2-12
On a particular chip with a particular code, the different modulation schemes are output in sequence. The code may be output in each of the 16 modulation schemes, with a dormant state, where all the outputs are disabled, for a set duration between. The output sequence may be:
Monopole-2
E0/E1-2
E0/E2-2
E1-E2-2
Beacon-3
E0/E1-4
E0/E2-4
E1-E2-4
Beacon-6
E0/E1-6
E0/E2-6
E1-E2-6
Beacon-12
E0/E1-12
E0/E2-12
E1-E2-12
The present invention also allows the possibility that, where appropriate, each pharmaceutical batch can be provided with a batch specific address. This allows identification of where the pill was made, when the pill was made, and in what batch it was made. In some cases, each pill will have a unique identifier. This would be particularly useful when drugs are more likely to be subsequently stolen or used illicitly, and thus should be tracked, or where questions of contamination may arise.
According to one embodiment, mux 65 produces a control voltage, which encodes the address serially and is used to vary the output frequency of oscillator 61. By example, when the control voltage is low, that is, when the serial address bit is at a 0, a 1 megahertz signal is generated by the oscillator. When the control voltage is high, that is, when the address bit is a 1, a 2 megahertz signal is generated the oscillator. Alternately, this can be 10 megahertz and 20 megahertz, or a phase shift keying approach where the device is limited to modulating the phase. The purpose of mux 65 is to control the frequency of the oscillator or an AC alternative embodiment of the amplified signal of oscillation.
The outputs of mux 65 are coupled to electrode drive 66 having at least three signal transmission elements, e.g., electrodes (shown in the figure as E0, E1 and E2) which can drive the signal transmission element in a variety of formats, e.g., monopole, dipole, etc., to provide a multidirectional transmission of the identifying signal. In this manner, the device broadcasts the sequence of 0's and 1's which constitute the address stored in mux 65. The address (i.e., identifying signal) may be broadcast repeatedly, as desired. Other configurations for the signal generation component are of course possible.
Other configurations of interest include, but are not limited to: those described in copending PCT application serial no. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.
As summarized above, the multi-directional transmitter component of the identifier is configured to transmit an identifying signal in multiple directions. As used herein, the term “multi-directional” means that the signal is at least transmitted in three different directions in a given plane. For example, the signal is transmitted in a first, second and third direction in a given x-y plane, such as a plane in which all the signal generation elements or a portion of thereof lie. In such embodiments, the magnitude of the angle between two different adjacent directions may vary, where it may range from 10 to 200°, such as from 50 to about 150°, e.g., 120°.
The identifier comprising the transmitter may be configured to transmit the signal simultaneously from each distinct signal transmission element, or be configured to sequentially transmit the signal from each signal transmission element. In the latter embodiment, the transmitter may be configured to transmit the signal sequentially from the signal transmission elements in a manner sufficient to provide for multi-directional transmission of the signal over a given period of time, e.g., as described above. For example, the identifier comprising the transmitter can be configured to sequentially transmit from at least three different transmission elements to transmit an identifying signal in more than one direction over a given time period.
For example, in the embodiment shown in
In the sequential embodiments of the invention, some of which are illustrated in
A variation of the sequential dipole transmission format illustrated in
Where sequential transmission is employed, the transmitter may be configured to transmit a complete identifying signal from a first transmission element before moving on to a second transmission element. As such, a transmission event from a transmission element includes transmission of a complete signal from the element, before moving on to transmit the signal from another transmission element.
In yet other embodiments, the transmitter may be configured to sequentially transmit only a portion, e.g., a bit, of an identifying signal from a given element before moving on to the next element. As such, the first portion of a signal will be transmitted from all the transmission elements and then the next portion of the signal will be transmitted from all the transmission elements and so on, until the complete identifier signal has been intermittently or sequentially transmitted (e.g., bit by bit) from each of the transmission elements.
Where the signal is sequential broadcast in multiple directions, the signal may be broadcast once in each direction or several times in each direction, such that the sequential transmission is cycled 2 or more times, e.g., 3 or more times, 4 or more times, 5 or more times, 10 or more times, as desired.
The transmitter may included dedicated circuitry which is configured to provide for the desired transmission protocol, e.g., sequential transmission protocol, as described above. An embodiment of such circuitry is illustrated schematically in
In the example shown here, the cycle counter 103 employed in
The control_psk 126 detailed in
As reviewed in
In the beacon states the counts are by 2, 3, 6, or 12, and in the binary states the counts are by 3, 4, 6 or 12. In a production device there can be various combinations of the controller states. For example, there can be one or two controllers, e.g. three beacon states or one beacon state with three binary states. To have all the various different combinations is more of a test bed model to demonstrate the various frequencies. In one embodiment, the same chip can be hardwired for a specific frequency (e.g. frequency 2) and disregard frequencies 1, 3 and 4. In yet other embodiments, the chip maybe configured by programming. The primary information that can be programmed are the addresses.
The transmitter may be configured such that it mechanically sweeps through multiple orientations during signal transmission. The mechanically sweeping multi-directional transmitter provides signal transmission in multiple directions utilizing as few as two electrodes. This reduces the size, complexity, and power requirements of the transmitter. The switching circuitry is not required when only two electrodes are used to transmit, lessening the complexity of the transmitter while still providing multi-directional transmission. In other embodiments, the mechanically sweeping properties can be incorporated into a multi-dimensional transmitter which electrically switches through multiple transmit orientations, giving another source of multi-directionality.
The transmitter can be located on a flexed body, such that two or more electrodes are located along the flexed body and separated from each other. One of the electrodes can be incorporated into the circuitry which drives the transmission, and can include the power source. Alternatively, the circuitry and/or power source can be located at a third location. The two electrodes can be electrically connected by a conductor which is located in or on the surface of the flexed body. The flexed body can be embedded or placed in the capsule in a twisted and/or bent shape such that the electrodes are aligned in a first orientation. As the pill dissolves, the transmitter body will be allowed to unfurl to a second orientation. During the signal sweeping process, the electrodes sweep through many different dipole orientations in three dimensions, allowing the identifier signal to be transmitted in multiple directions. The signal sweeping process may last about 1 second to about 8 hours, more specifically about 30 seconds to about 3 hours, most specifically about 10 minutes.
The flexed body can be made of a variety of materials, such as plastics or metals, that have the desired elastic and shape memory properties. It is important for the flexed body to be easily twisted and bent into the desired first configuration, but retain shape memory so that it deploys to a second configuration once released from the encapsulation layer. There are many shape memory alloys known in the art, such as nickel titanium alloys, which change shape in response to a temperature change. These materials can be used in the flexed body, so that the flexed body will return to its memory shape when exposed to the temperature of the body. In some embodiments, the flexed body can be made of an indigestible material which will pass through the body. Because the transmitter will be small and in many cases flexible, it will pass through the body without harmful effects. In other embodiments, the flexed body can be made of a digestible material, which will break down over time. The flexed body can be made of a material which will not completely break down until signal transmission is complete.
The conductor which connects the electrodes can be a flexible wire which can be embedded into the flexed body. In the cases where the flexed body dissolves, the flexible conductive wire will remain, but will easily pass through the body due to its flexibility. Alternatively, a thin layer of a conductor, such as gold, can be deposited on the surface of the flexed body to connect the electrodes. The conductor can also be made of a material which will dissolve, such as edible gold foil. This would leave the chip as the only indigestible portion of the transmitter, which will pass through the body.
In some cases, it may be desirable for the transmitter not to deploy at the same time the pill dissolves. One way to add a delay is to coat the transmitter in with a material which does not dissolve in the same environment as the pill material. For instance, cellulose acetate phthalate can be used as an enteric coating to coat the transmitter, causing it not to dissolve in the acidic environment of the stomach, but to dissolve in the small intestine. Because the onboard battery is not activated until it becomes wet, the transmitter will not begin signal transmission until the coating dissolves.
In some embodiments, multiple transmitters can be used in a single pill. This increases the likelihood that the pill will be detected by the receiver. Also, if the transmitters are located at different depths in the pill, or coated with different substances, this can give valuable information. For instance, if one transmitter is configured to begin transmission when it enters the stomach, and another is configured to begin transmission when it enters the small intestine, this can give an indication of motility by tracking how long it takes for the pill to travel from the stomach to the small intestine.
As the pill enters the desired location in the body, such as the stomach, it begins to dissolve.
As shown in
It should be noted that the signal sweeping process is continuous, and the orientation of the electrodes will be continuously changing during the process.
In a healthy stomach, the transmitter may naturally change orientation due to contractions in the stomach, giving some degree of multi-directionality. In these cases, the multi-directional transmitter can serve to supplement the natural rotations. Also, in cases where the pill and/or transmitter is stuck on a wall, or in a less active portion of the stomach or digestive tract, the multi-directionality of the transmitter is even more important. For instance, the pill and/or transmitter can become stuck in the ruggae, or a less active region of the stomach such as the fundus. The sweeping motion of the transmitter may also serve to dislodge the pill and/or transmitter if it is stuck. Some patients suffer from low stomach activity, and may especially benefit from a pill with a multi-directional transmitter.
The multi-directional transmitter discussed above is not limited to use in conjunction with a pharmaceutical pill. The transmitter can be disposed on a sensor or other unit which travels or is implanted in the body, in order to wirelessly transmit data in multiple directions.
As reviewed above, the circuitry that drives the identifier may include a number of different functional blocks, e.g., signal generation blocks, activation blocks, transmitter blocks, a power source, etc. In certain embodiments, these functional blocks are provided in the form of an integrated circuit, where the integrated circuits of these embodiments include a number of distinct functional blocks, i.e., modules, where the functional blocks are all present in a single integrated circuit on an intraluminal-sized support. By single integrated circuit is meant a single circuit structure that includes all of the different functional blocks. As such, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain embodiments of the present invention are distinct from hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
The support with which the circuit is associated, e.g., by being present on surface of the support or integrated, at least partially, inside of the support, may be any convenient support, and may be rigid or flexible as desired. As the support is intraluminal sized, its dimensions are such that it can be positioned inside of a physiological lumen, e.g., inside of a vessel, such as a cardiac vessel, e.g., a vein or artery. In certain embodiments, the intraluminal sized integrated circuits have a size (e.g., in terms of surface area of largest surface) of between about 0.05 mm2 and about 5 mm2, such as between about 1.125 mm2 and about 2.5 mm2, and including about 1.5 mm2. The supports of the integrated circuits can have a variety of different shapes, such as square, rectangle, oval, and hexagon, irregular, etc.
The transmitter may include dedicated circuitry which is configured to provide for the desired transmission protocol.
As reviewed above, the circuitry that drives the identifier may include a number of different functional blocks, e.g., signal generation blocks, activation blocks, transmitter blocks, etc. In certain embodiments, these functional blocks are provided in the form of an integrated circuit, where the integrated circuits of these embodiments include a number of distinct functional blocks, i.e., modules, where the functional blocks are all present in a single integrated circuit on an intraluminal-sized support. By single integrated circuit is meant a single circuit structure that includes all of the different functional blocks. As such, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain embodiments of the present invention are distinct from hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
The support with which the circuit is associated, e.g., by being present on surface of the support or integrated, at least partially, inside of the support, may be any convenient support, and may be rigid or flexible as desired. As the support is intraluminal sized, its dimensions are such that it can be positioned inside of a physiological lumen, e.g., inside of a vessel, such as a cardiac vessel, e.g., a vein or artery. In certain embodiments, the intraluminal sized integrated circuits have a size (e.g., in terms of surface area of largest surface) of between about 0.05 mm2 and about 5 mm2, such as between about 1.125 mm2 and about 2.5 mm2, and including about 1.5 mm2. The supports of the integrated circuits can have a variety of different shapes, such as square, rectangle, oval, and hexagon, irregular, etc.
Other configurations for the circuitry are of course possible. Other configurations of interest include, but are not limited to, those described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; PCT application serial no. PCT/US2007/022257 filed on Oct. 17, 2007 and titled “In-vivo Low Voltage Oscillator for Medical Devices”; PCT application serial no. PCT/US US2007/82563 filed on Oct. 25, 2007 and titled “Controlled Activation Ingestible Identifier”; U.S. patent application Ser. No. 11/776,480 filed Jul. 11, 2007 entitled “Acoustic Pharma Informatics System”; and PCT application serial no. PCT/US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; the disclosures of which applications (and particularly signal generation components thereof) are herein incorporated by reference.
The identifiers may be fabricated using any convenient processing technology. In certain embodiments, planar processing protocols are employed to fabricate power sources having surface electrodes, where the surface electrodes include at least an anode and cathode at least partially on the same surface of a circuitry support element. In some embodiments, the power source can comprise a battery. In certain embodiments, planar processing protocols are employed in a wafer bonding protocol to produce a battery source. Planar processing techniques, such as Micro-Electro-Mechanical Systems (MEMS) fabrication techniques, including surface micromachining and bulk micromachining techniques, may be employed. Deposition techniques that may be employed in certain embodiments of fabricating the structures include, but are not limited to: electrodeposition (e.g., electroplating), cathodic arc deposition, plasma spray, sputtering, e-beam evaporation, physical vapor deposition, chemical vapor deposition, plasma enhanced chemical vapor deposition, etc. Material removal techniques included, but are not limited to: reactive ion etching, anisotropic chemical etching, isotropic chemical etching, planarization, e.g., via chemical mechanical polishing, laser ablation, electronic discharge machining (EDM), etc. Also of interest are lithographic protocols. Of interest in certain embodiments is the use of planar processing protocols, in which structures are built up and/or removed from a surface or surfaces of an initially planar substrate using a variety of different material removal and deposition protocols applied to the substrate in a sequential manner. Illustrative fabrication methods of interest are described in greater detail in copending PCT application serial no. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.
Optional Physiologically Acceptable Carrier Component
Identifiers of the invention that include multi-directional transmitters as described above may be present in (i.e., combined with) a physiologically acceptable carrier component, e.g., a composition or vehicle that aids in ingestion of the identifier and/or protects the identifier until it reaches the target site of interest. By physiologically acceptable carrier component” is meant a composition, which may be a solid or fluid (e.g., liquid), which has is ingestible.
Common carriers and excipients, such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid are of interest. Disintegrators commonly used in the formulations of the invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
A liquid composition may comprise a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder. For example, a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
A composition in the form of a tablet or pill can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example, polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
“Controlled release”, “sustained release”, and similar terms are used to denote a mode of active agent delivery that occurs when the active agent is released from the delivery vehicle at an ascertainable and controllable rate over a period of time, rather than dispersed immediately upon application or injection. Controlled or sustained release may extend for hours, days or months, and may vary as a function of numerous factors. For the pharmaceutical composition of the present invention, the rate of release will depend on the type of the excipient selected and the concentration of the excipient in the composition. Another determinant of the rate of release is the rate of hydrolysis of the linkages between and within the units of the polyorthoester. The rate of hydrolysis in turn may be controlled by the composition of the polyorthoester and the number of hydrolysable bonds in the polyorthoester. Other factors determining the rate of release of an active agent from the present pharmaceutical composition include particle size, acidity of the medium (either internal or external to the matrix) and physical and chemical properties of the active agent in the matrix.
A composition in the form of a capsule can be prepared using routine encapsulation procedures, for example, by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example, liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
Other components suitable for use in the formulations of the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).
Optional Active Agent
In certain embodiments, the identifier is not associated with a pharmaceutically active agent. As such, the identifier, and any carrier or other component that make up the ingestible event marker, do not include an active agent.
In yet other embodiments, the identifier is associated with an active agent, e.g., where the active agent is present in the carrier composition that includes the identifier. In some embodiments, the signal generation element can be stably associated with an active agent. By “active agent/carrier component” is meant a composition, which may be a solid or fluid (e.g., liquid), which has an amount of active agent, e.g., a dosage, present in a pharmaceutically acceptable carrier. The active agent/carrier component may be referred to as a “dosage formulation.”
“Active agent” includes any compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Active agents are distinguishable from such components as vehicles, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. The active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject. In certain embodiments, the active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication. In certain embodiments, the active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.
The active agent (i.e., drug) is capable of interacting with a target in a living subject. The target may be a number of different types of naturally occurring structures, where targets of interest include both intracellular and extracellular targets. Such targets may be proteins, phospholipids, nucleic acids and the like, where proteins are of particular interest. Specific proteinaceous targets of interest include, without limitation, enzymes, e.g., kinases, phosphatases, reductases, cyclooxygenases, proteases and the like, targets comprising domains involved in protein-protein interactions, such as the SH2, SH3, PTB and PDZ domains, structural proteins, e.g., actin, tubulin, etc., membrane receptors, immunoglobulins, e.g., IgE, cell adhesion receptors, such as integrins, etc., ion channels, transmembrane pumps, transcription factors, signaling proteins, and the like.
The active agent (i.e., drug) may include one or more functional groups necessary for structural interaction with the target, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions, depending on the particular drug and its intended target. Where the target is a protein, the drug moiety may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, such as at least two of the functional chemical groups.
Drugs of interest may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Also of interest as drug moieties are structures found among biomolecules, including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.
The active agent may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including the preparation of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
As such, the active agent may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library. When obtained from such libraries, the drug moiety employed will have demonstrated some desirable activity in an appropriate screening assay for the activity. Combinatorial libraries, as well as methods for producing and screening such libraries, are known in the art and described in: U.S. Pat. Nos. 5,741,713; 5,734,018; 5,731,423; 5,721,099; 5,708,153; 5,698,673; 5,688,997; 5,688,696; 5,684,711; 5,641,862; 5,639,603; 5,593,853; 5,574,656; 5,571,698; 5,565,324; 5,549,974; 5,545,568; 5,541,061; 5,525,735; 5,463,564; 5,440,016; 5,438,119; 5,223,409, the disclosures of which are herein incorporated by reference.
Broad categories of active agents of interest include, but are not limited to: cardiovascular agents; pain-relief agents, e.g., analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents; chemotherapeutic (e.g., anti-neoplastic) agents; etc.
A variety of manufacturing protocols may be employed to produce compositions as described above, e.g., where an identifier is present in pharmaceutically acceptable carrier or vehicle, where the carrier or vehicle may further include one or more active agents. In manufacturing such compositions, an identifier is stably associated with the pharmaceutical dosage from in some manner. By stably associated is meant that the identifier and the dosage form do not separate from each other, at least until administered to the subject in need thereof, e.g., by ingestion. The identifier may be stably associated with the pharmaceutical carrier/active agent component of the composition in a number of different ways. In certain embodiments, where the carrier/active agent component is a solid structure, e.g., such as a tablet or pill, the carrier/active agent component is produced in a manner that provides a cavity for the identifier. The identifier is then placed into the cavity and the cavity sealed, e.g., with a biocompatible material, to produce the final composition. For example, in certain embodiments a tablet is produced with a die that includes a feature which produces a cavity in the resultant compressed tablet. The identifier is placed into the cavity and the cavity sealed to produce the final tablet. In a variation of this embodiment, the tablet is compressed with a removable element, e.g., in the shape of a rod or other convenient shape. The removable element is then removed to produce a cavity in the tablet. The identifier is placed into the cavity and the cavity sealed to produce the final tablet. In another variation of this embodiment, a tablet without any cavity is first produced and then a cavity is produced in the tablet, e.g., by laser drilling. The identifier is placed into the cavity and the cavity sealed to produce the final tablet. In yet other embodiments, a tablet is produced by combining the identifier with subparts of the tablet, where the subparts may be pre-made subparts or manufactured sequentially. For example, in certain embodiments tablets are produced by first making a bottom half of the tablet, placing the signal generation element on a location of the bottom half of the tablet, and then placing top portion of the tablet over the bottom half and signal generation element to produce the final desired composition. In certain embodiments, a tablet is produced around an identifier such that the identifier is located inside of the produced tablet. For example, an identifier, which may or may not be encapsulated in a biocompatible compliant material, e.g., gelatin (to protect the signal generation element), is combined with carrier/active agent precursor, e.g., powder, and compressed or molded into a tablet in a manner such that the identifier is located at an internal position of the tablet. Instead of molding or compressing, the carrier/active agent component is, in certain embodiments, sprayed onto an identifier in a manner that builds up the tablet structure. In yet another embodiment, the active agent/carrier component precursor may be a liquid formulation which is combined with the identifier and then solidified to produce the final composition. In yet other embodiments, pre-made tablets may be fitted with an identifier by stably attaching an identifier to the tablet. Of interest are protocols that do not alter the properties of the tablet, e.g., dissolution etc. For example, a gelatin element that snap fits onto one end of a tablet and has an identifier integrated with it is employed in certain embodiments. The gelatin element is colored in certain embodiments to readily identify tablets that have been fitted with the signal generation element. Where the composition has an active agent/carrier composition filled capsule configuration, e.g., such as a gelatin capsule filled configuration, an identifier may be integrated with a capsule component, e.g., top or bottom capsule, and the capsule filled with the active agent/carrier composition to produce the final composition. The above reviewed methods of manufacture are merely illustrative of the variety of different ways in which the compositions of the invention may be manufactured.
In certain embodiments, the identifiers are disrupted upon administration to a subject. As such, in certain embodiments, the compositions are physically broken, e.g., dissolved, degraded, eroded, etc., following delivery to a body, e.g., via ingestion, injection, etc. The compositions of these embodiments are distinguished from devices that are configured to be ingested and survive transit through the gastrointestinal tract substantially, if not completely, intact.
Systems
Also provided are systems that include the subject compositions. Systems of the subject invention include, in certain embodiments, an ingestible or implantable event marker comprising one or more devices that include a deployable antenna of the invention, e.g., an identifier as reviewed above, as well as a signal detection component, e.g., in the form of a receiver. The signal detection component may vary significantly depending on the nature of the signal that is generated by the signal generation element of the composition, e.g., as reviewed above.
Signal receivers of systems of embodiments of the invention are those that are configured to receive a signal from an identifier, e.g., to receive a signal emitted by an identifier upon contact of the identifier with the target physiological site following ingestion of the identifier. The signal receiver may vary significantly depending on the nature of the signal that is generated by the signal generation element, e.g., as reviewed below. As such, the signal receiver may be configured to receive a variety of different types of signals, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc., as indicated above. In certain embodiments, the receiver is configured to receive a signal conductively from another component, e.g. the identifier, such that the two components use the body of the patient as a communication medium. As such, the signal that is transferred between identifier and the receiver travels through the body, and requires the body as the conduction medium. The identifier emitted signal may be transmitted through and received from the skin and other body tissues of the subject body in the form of electrical alternating current (a.c.) voltage signals that are conducted through the body tissues. As a result, such embodiments do not require any additional cable or hard wire connection, or even a radio link connection for transmitting the sensor data from the autonomous sensor units to the central transmitting and receiving unit and other components of the system, since the sensor data are directly exchanged via the skin and other body tissues of the subject. This communication protocol has the advantage that the receivers may be adaptably arranged at any desired location on the body of the subject, whereby the receivers are automatically connected to the required electrical conductor for achieving the signal transmission, i.e., the signal transmission is carried out through the electrical conductor provided by the skin and other body tissues of the subject. In certain embodiments, the signal detection component is one that is activated upon detection of a signal emitted from an identifier. In certain embodiments, the signal receiver is capable of (i.e., configured to) simultaneously detecting multiple different signals, e.g., 2 or more, 5 or more, 10 or more, etc.
The signal receiver may include a variety of different types of signal receiver elements, where the nature of the receiver element necessarily varies depending on the nature of the signal produced by the signal generation element. In certain embodiments, the signal receiver may include one or more electrodes (e.g., 2 or more electrodes, 3 or more electrodes, and/or includes multiple, e.g., 2 or more, 3 or more, 4 or more pairs of electrodes, etc.) for detecting signal emitted by the signal generation element. In certain embodiments, the receiver device will be provided with two electrodes that are dispersed at a distance, e.g., a distance that allows the electrodes to detect a differential voltage. This distance may vary, and in certain embodiments ranges from about 0.1 to about 5 cm, such as from about 0.5 to about 2.5 cm, e.g., about 1 cm. In an alternative embodiment, a receiver that utilizes a single electrode is employed. In certain embodiments, the signal detection component may include one or more coils for detecting signal emitted by the signal generation element. In certain embodiments, the signal detection component includes an acoustic detection element for detecting signal emitted by the signal generation element. In certain embodiments, multiple pairs of electrodes (e.g., as reviewed above) are provided, for example to increase detection probability of the signal.
The signal receivers of interest include both external and implantable signal receivers. In external embodiments, the signal receiver is ex vivo, by which is meant that the receiver is present outside of the body during use. Where the receiver is implanted, the signal receiver is in vivo. The signal receiver is configured to be stably associated with the body, e.g., either in vivo or ex vivo, at least during the time that it receives the emitted signal from the IEM.
Signal receivers of interest include, but are not limited to, those receivers disclosed in: PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; and PCT application serial no. PCT/US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; the disclosures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference.
In certain embodiments, the signal receiver is configured to provide data of a received signal to a location external to said subject. For example, the signal receiver may be configured to provide data to an external data receiver, e.g., which may be in the form of a monitor (such as a bedside monitor), a computer (e.g., PC or MAC), a personal digital assistant (PDA), phone, messaging device, smart phone, etc. In one embodiment, if a signal receiver failed to detect a signal indicating that a pill had been ingested, the signal receiver could transmit a reminder to take the pill to the subject's PDA or smart phone, which could then provide a prompt to the user to take the medication, e.g., a display or alarm on the PDA, by receiving a phone call on the smart phone (e.g., a recorded message) etc. The signal receiver may be configured to retransmit data of a received signal to the location external to said subject. Alternatively, the signal receiver according may be configured to be interrogated by an external interrogation device to provide data of a received signal to an external location.
As such, in certain embodiments the systems include an external device which is distinct from the receiver (which may be implanted or topically applied in certain embodiments), where this external device provides a number of functionalities. Such an apparatus can include the capacity to provide feedback and appropriate clinical regulation to the patient. Such a device can take any of a number of forms. By example, the device can be configured to sit on the bed next to the patient, e.g., a bedside monitor. Other formats include, but are not limited to, PDAs, smart phones, home computers, etc. The device can read out the information described in more detail in other sections of the subject patent application, both from pharmaceutical ingestion reporting and from physiological sensing devices, such as is produced internally by a pacemaker device or a dedicated implant for detection of the pill. The purpose of the external apparatus is to get the data out of the patient and into an external device. One feature of the external apparatus is its ability to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency.
Methods
Aspects of the invention further include methods of using in-body devices that include transmitters of the invention. Generally, methods of the invention will include placing the in-body device in some manner in the body of the subject, e.g., by implanting the device in a subject, by ingesting the device, etc. The devices may be employed with a variety of subjects. Generally such subjects are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In certain embodiments, the subjects will be humans. Following placement of the devices in the body of a subject, the devices are employed for a variety of purposes, e.g., to sense one or more physiological parameters, to deliver one or more therapies, to mark a personal event of interest, etc.
In certain embodiments, the in-body devices are ingestible devices, where the transmitter is part of an identifier of the device. In such embodiments, the identifier is ingested and a signal emitted by the identifier is detected, e.g., with a receiver as described above. Such methods are further described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; and PCT application serial no. PCT/US US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; the disclosures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference.
Utility
Devices that include the multi-directional transmitters of the invention may be employed in a variety of different applications, including both therapeutic and non-therapeutic applications. Specific applications of interest include, but are not limited to: those applications described in PCT application serial no. PCT/US2006/016370 filed on Apr. 28, 2006 and titled “Pharma-Informatics System”; and PCT application serial no. PCT/US US2008/52845 filed on Feb. 1, 2008 and titled “Ingestible Event Marker Systems”; the disclosures of which applications (and particularly signal receiver components thereof) are herein incorporated by reference.
IEM in body devices of the invention may be employed in a variety of different applications, which applications may be both medical and non-medical in nature. Different illustrative applications are now reviewed in greater detail below.
Certain applications involve the use of IEMs by themselves to mark a personal event of interest, e.g., onset of a physiological parameter (such as a symptom(s) of interest), onset of an activity, etc. For example, in certain embodiments, event markers are employed to mark the onset of a symptom of interest. In such instances, when an individual becomes aware of a symptom of interest, e.g., begins to feel flushed, nauseous, excited, etc., e.g., the individual may ingest an IEM to mark the occurrence of the symptom of interest. For example, the patient may begin to not feel well, and ingest an event marker in response to this ill feeling. Upon ingestion, the marker sends a signal to a receiver, which may then record receipt of the signal for further use, e.g., to combine with physiological data, etc. In certain embodiments, the received signal is employed to provide context for any physiological data that is obtained from the patient, e.g., by sensors on the receiver, from an implantable recorder, etc.
Another symptom of interest is pain. In these embodiments, the ingestible event marker may be employed as a pain marker. For example, in the case where a patient is being monitored for pain, if a patient feels no pain, the patient may ingest a first type of marker. If the patient feels pain, the patient may ingest a second type of marker. Different types of markers may be differentiated, such as color coded, where desired, to assist in their identification and proper use by the patient. For example, markers to be ingested when the patient does not feel pain may be color coded blue, while markers that are to be ingested when the patient does have pain may be color coded yellow. In another embodiment, instead of having different types of markers, a protocol may be employed in which the number of markers ingested, and therefore the signal obtained, e.g., from a single marker or two or more markers, is employed to denote a scale of the symptom of interest, such as pain. For example, if an individual is having intense pain, the individual takes four of the positive pain marker pills at the same time, while in response to mild pain the individual may take only one marker.
In such embodiments, the onset of the symptom of interest, as marked by the ingestion of the event marker and detection of the signal by the receiver, may be employed as relevant point at which to begin recording one or more physiological parameters of interest, e.g., by using an implantable physiological monitor. In these instances, the emitted signal from the marker is received by the receiver, which then causes a physiological parameter recorder (such as a Reveal® Plus Insertable Loop Recorder (ILR), Medtronic Corporation) to begin recording data and saving the data, e.g., for later use. For example, an implantable physiological parameter recorder may have only a limited possible amount of time for recording (such as 42 minutes). In such situations, the data may be automatically overwritten unless somehow flagged or marked for protection. In the present methods, an IEM may be ingested to mark the onset of a symptom of interest, as perceived by the patient, and the receiver upon receipt of the signal may act with the recorder to protect the data obtained around the time of the signal (after, or even some time before) to be protected and not overwritten. The system may be further configured to work in response not only to the ingestion of the event marker, but also in response to physiological sensed parameters, e.g., pH. As such, the methods find use as an event recorder in terms of flagging a diagnostic stream of information, and protecting it from being overwritten, so a physician can look at it at a later date.
In certain embodiments, the event marker provides the context for interpreting a given set of physiological data at a later time. For example, if one is employing an activity sensor and one co-administers an event marker with a particular drug, one can note any change in activity that is brought about by that drug. If a drop in activity is observed after a person takes both the event marker and a drug, the drop indicates the drug is probably causing the person to reduce their activity, e.g., by making them feel sleepy or actually causing them to fall asleep. Such data may be employed to adjust the dose of a drug or be the basis for a decision to switch to an alternative medication.
In certain embodiments the event marker is employed to construct a database of multiple events. Such a database may be employed to find commonality between the multiple marked events. Simple or complex protocols for finding commonality among multiple marked events may be employed. For example, multiple events may be averaged. Alternatively techniques such as impulse response theory may be employed, where such techniques provide information on what exactly are the common features in a set of multiple sensor streams that are tied to a particular event.
The IEM systems of the invention enable one to use subjective symptoms, such as “I'm feeling funny,” to impart context and background to obtained objective measures of what is occurring physiologically. For example, if every time a subject felt abnormal they took an event marker, one could reference a database of the objective sensor data, and find common features in the database. Such an approach may be employed to discover the underlying causes of the subjective feeling. For example, such an approach may be employed to determine that every time a patient is feeling “funny”, there is an associated change in their blood pressure, and the link between a subjective symptom and objective physiological data can be used in their diagnosis. As such, a generalizable event marker brings context to discrete data from any other source. Therefore, use of the oral medication event markers can provide context for any other associated health monitoring information or health event.
In certain embodiments, the event marker can be an alert marker, such that ingestion of the marker causes an alarm signal to be sent from the patient, e.g., indicating that the patient needs medical assistance. For example, when a patient feels an onset of a symptom of interest, such as chest pain, shortness of breath, etc., the patient may ingest an event marker. The signal emitted from the event marker may be received by the receiver, which may then cause an alarm to be generated and distributed to a medical professional.
In certain embodiments, the event marker is employed to instigate or start a therapeutic action, e.g., activate an implantable pulse generator to deliver electrical therapy, activate an implanted drug delivery device to administer a dosage of drug, activate a physiological sensor to begin acquiring data, etc. For example, where a patient has a neural stimulator for treating migraines, upon perception of the onset of aura, the patient could ingest an IEM. The emitted signal would then activate neural stimulator into stimulus mode, and thereby cause the implant to deliver therapy. Alternatively, if one has an implanted drug deliver device, e.g., a device that delivers an oncotic agent, ingestion of the IEM could cause the implanted device to deliver the active agent.
In certain embodiments, the event marker is employed to deliver information to an implanted medical device in the patient. For example, an ingestible event marker may send a signal that includes update data for an implanted medical device, such as firmware upgrade data for an implantable pulse generator, e.g., a pace maker. In such instances, the signal may include the upgrade code which is broadcast from the IEM conductively to the medical device, where upon receipt of the signal and code, the firmware of the medical device is upgraded.
Other applications where event markers may be employed by themselves is to mark or note the start of non-medical personal event, such as a commute time, the start of an exercise regimen, sleep time, smoking (e.g., so one can log how much one smokes) etc.
As indicated above, embodiments of the invention are characterized in that the event markers are co-ingested with another composition of matter, e.g., a pharmaceutical composition, food, etc, where the event marker may or may not be present in the same composition as the co-ingested matter. For example, the event markers may be employed to track ingesting a pharmaceutical agent, where one co-administers the marker with the drug of interest. Applications where co-administration of a drug and marker is of interest include, but are not limited to, clinical studies, titration of medicine, e.g., blood pressure medicine, etc. Where desired, the IEM could be provided as just another pill to indicate when a refill is needed from the pharmacy.
Instead of co-ingesting the event marker with another composition, e.g., a drug, food, etc., the marker and the other composition may be compounded together, e.g., by the end user. For example, an IEM in the form of a capsule can be opened by the end user and filled with a pharmaceutical composition. The resultant compounded capsule and active agent may then be ingested by the end user. Instead of an end user, the pharmacist or a health care provider may perform the compounding step.
In yet other embodiments, the marker is present already compounded with the other composition at the source of manufacture of the other composition, e.g., the manufacturer or producer of a pharmaceutical composition. An example of such compositions includes those described in PCT application serial no. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.
In certain embodiments, the IEMs of the invention are employed to allow one to look at, on an individual basis, what a given result is with respect to what drugs an individual is taking versus their impact on indicators that correlate to the desired effect. For example, where a given patient is prescribed a regimen of multiple pharmaceutical agents and there are multiple different physiological parameters that are monitored as indicators of how the patient is responding to the prescribed therapeutic regimen, a given drug as marked by a given marker can be assessed in terms of its impact on one or more of the physiological parameters of interest. Following this assessment, adjustments can be made accordingly. In this manner, automation may be employed to tailor therapies based on individual responses. For example, where a patient is undergoing oncotic therapy, the event marker can be used to provide real time context to obtained physiological parameter data. The resultant annotated real time data can be used to make decisions about whether or not to continue therapy, or change to a new therapy.
In certain embodiments, a dosing event (as marked by the IEM) is correlated with sensor data to develop a profile for how a given drug acts, e.g., in terms of a pharmacokinetic and/or pharmacodynamic model. Sensors are employed with the IEM marking of the dosing event to obtain a pharmacokinetic model. Once a pharmacokinetic model is derived, one can use the dosing event to drive that model and predict serum drug levels and response. One might find, as determined from various sensors, that a patient is not responding well to therapy at a particular time. One might look back at the pharmacokinetic model to find that the levels of the therapeutic drug in the blood are low when the patient is not responding well, based on symptoms and/or objective physiological data. This data can then be used to make a determination to increase the dosing frequency or increase the dose level at a given dosing event. The event marker can therefore provide provides a way to develop a pharmacokinetic and/or pharmacodynamic model and then apply it to optimize patient therapy.
Where the IEMs are co-administered with a pharmaceutical agent, e.g., as two separate compositions or a single composition (as described above), the systems of the invention, enable a dynamic feedback and treatment loop of tracking medication timing and levels, measuring the response to therapy, and recommending altered dosing based on the physiology and molecular profiles of individual patients. For example, a symptomatic heart failure patient takes multiple drugs daily, primarily with the goal of reducing the heart's workload and improving patient quality of life. Mainstays of therapy include angiotensin converting enzyme (ACE) inhibitors, β-blockers and diuretics. For pharmaceutical therapy to be effective, it is vital that patients adhere to their prescribed regimen, taking the required dose at the appropriate time. Multiple studies in the clinical literature demonstrate that more than 50% of Class II and III heart failure patients are not receiving guideline-recommended therapy, and, of those who are titrated appropriately, only 40-60% adhere to the regimen. With the subject systems, heart failure patients can be monitored for patient adherence to therapy, and adherence performance can be linked to key physiologic measurements, to facilitate the optimization of therapy by physicians.
In certain embodiments, the systems of the invention may be employed to obtain an aggregate of information that includes sensor data and administration data. For example, one can combine the heart rate, the respiration rate, multi-axis acceleration data, something about the fluid status, and something about temperature, and derive indices that will inform about the total activity of the subject, that can be used to generate a physiological index, such as an activity index. For instance, when there is a rise in temperature, heart rate goes up a bit, and respiration speeds up, which may be employed as an indication that the person is being active. By calibrating this, the amount of calories the person is burning at that instant could be determined. In another example, a particular rhythmic set of pulses or multi-axis acceleration data can indicate that a person is walking up a set of stairs, and from that one can infer how much energy they are using. In another embodiment, body fat measurement (e.g. from impedance data) could be combined with an activity index generated from a combination of measured biomarkers to generate a physiological index useful for management of a weight loss or cardiovascular health program. This information can be combined with cardiac performance indicators to get a good picture of overall health, which can be combined with pharmaceutical therapy administration data. In another embodiment, one might find for example that a particular pharmaceutical correlates with a small increase in body temperature, or a change in the electrocardiogram. One can develop a pharmacodynamic model for the metabolism of the drug, and use the information from the receiver to essentially fit the free parameters in that model to give much more accurate estimation of the levels actually present in the serum of the subject. This information could be fed back to dosing regimes. In another embodiment, one can combine information from a sensor that measures uterine contractions (e.g. with a strain gauge) and that also monitors fetal heart rate, for use as a high-risk pregnancy monitor.
In certain embodiments, the subject specific information that is collected using the systems of the invention may be transmitted to a location where it is combined with data from one or more additional individuals to provide a collection of data which is a composite of data collected from 2 or more, e.g., 5 or more, 10 or more, 25 or more, 50 or more, 100 or more, 1000 or more, etc., individuals. The composite data can then be manipulated, e.g., categorized according to different criteria, and made available to one or more different types of groups, e.g., patient groups, health care practitioner groups, etc., where the manipulation of data may be such as to limit the access of any given group to the type of data that group can access. For example, data can be collected from 100 different individuals that are suffering from the same condition and taking the same medication. The data can be processed and employed to develop easy to follow displays regarding patient compliance with a pharmaceutical dosage regimen and general health. Patient members of the group can access this information and see how their compliance matches with other patient members of the group, and whether they are enjoying the benefits that others are experiencing. In yet another embodiment, doctors can also be granted access to a manipulation of the composite data to see how their patients are matching up with patients of other doctors, and obtain useful information on how real patients respond to a given therapeutic treatment regiment. Additional functionalities can be provided to the groups given access to the composite data, where such functionalities may include, but are not limited to: ability to annotate data, chat functionalities, security privileges, etc.
The inventive pharmacokinetic model allows for drug dosing regimens to be adjusted in real time in response to varying serum levels in the body. The pharmacokinetic model can predict or measure the serum level of a given medication in the body. This data can then be used to calculate when the next dose of medication should be taken by the patient. An alarm can be triggered at that time to alert the patient to take a dose. If the serum level remains high, an alarm can be triggered to alert the patient not to take the next dose at the originally prescribed time interval. The pharmacokinetic model can be used in conjunction with a medication ingestion monitoring system that includes an IEM, such as that described above. Data from this system can be incorporated into the model, as well as population data, measured data, and data input by the patient. Utilizing data from multiple sources, a very powerful and accurate tool can be developed.
In some embodiments, the data gathered by the receiver can be used directly by the pharmacokinetic model to determine when a medication was administered, what medication it was and in what amount. This information can be used to calculate an estimate of the serum level of the medication in the patient. Based on the calculated serum level, the pharmacokinetic model can send an alert to the patient to say either that the serum level is too high and is near or above the toxic level, or that the serum level is too low and they should take another dose. The pharmacokinetic model can be run on the implanted receiver itself or on an external system which receives data from the implanted receiver.
A simple form of the pharmacokinetic model can assume that every patient is the same, and use average population data to model the serum level. A more complex and more accurate model can be obtained by inputting other information about the patient. This information can be inputted by the user, such as a physician, or gathered by the receiver from associated sensors. Information that can be used to adjust the model include other medications being taken, diseases the patient suffers from, patient's organ function, enzyme levels, metabolism, body weight, and age, among other factors. Information can also be inputted by the patient themselves, such as if they feel hypoglycemic, or have pain or dizziness. This can be used as further evidence to validate the predictions of the model.
Examples of food applications include the following. In certain disease conditions, such as diabetes, it can be important what a patient ate and when. In such instances, event markers of the invention are keyed or linked to the type of food a patient eats. For example, one can have a set of event markers for different food items, and one can co-administer them with the food items. From the resultant data, one can do a complete individual metabolic profile on an individual. One knows how many calories the patient is consuming. By obtaining activity and heart rate and ambient temperature versus body temperature data, one can calculate how many calories one is expending. As a result, guidance can be provided to the patient as to what foods to eat and when. Non disease patients may also track food ingestion in this manner. For example, athletes adhering to a strict training diet may employ IEMs to better monitor food ingestion and the effect of the food ingestion on one or more physiological parameters of interest.
As reviewed in the above discussion, IEM systems of the invention find use in both therapeutic and non-therapeutic applications. In therapeutic applications, the IEM may or may not be compounded with a pharmaceutically active agent. In those embodiments where the IEM is compounded with active agent, the resultant compounded composition may be viewed as a pharma-informatics enabled pharmaceutical composition.
In such pharma-informatics embodiments, an effective amount of a composition that includes an IEM and an active agent is administered to a subject in need of the active agent present in the composition, where “effective amount” means a dosage sufficient to produce the desired result, e.g. an improvement in a disease condition or the symptoms associated therewith, the accomplishment of a desired physiological change, etc. The amount that is administered may also be viewed as a therapeutically effective amount. A “therapeutically effective amount” means the amount that, when administered to a subject for treating a disease, is sufficient to effect treatment for that disease.
The composition may be administered to the subject using any convenient means capable of producing the desired result, where the administration route depends, at least in part, on the particular format of the composition, e.g., as reviewed above. As reviewed above, the compositions can be formatted into a variety of formulations for therapeutic administration, including but not limited to solid, semi solid or liquid, such as tablets, capsules, powders, granules, ointments, solutions, suppositories and injections. As such, administration of the compositions can be achieved in various ways, including, but not limited to: oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc., administration. In pharmaceutical dosage forms, a given composition may be administered alone or in combination with other pharmaceutically active compounds, e.g., which may also be compositions having signal generation elements stably associated therewith. In some embodiments, the signal generation element is stably associated with one or more active agents.
The subject methods find use in the treatment of a variety of different conditions, including disease conditions. The specific disease conditions treatable by with the subject compositions are as varied as the types of active agents that can be present in the subject compositions. Thus, disease conditions include, but are not limited to: cardiovascular diseases, cellular proliferative diseases, such as neoplastic diseases, autoimmune diseases, hormonal abnormality diseases, infectious diseases, pain management, and the like.
By treatment is meant at least an amelioration of the symptoms associated with the disease condition afflicting the subject, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the subject no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition. Accordingly, “treating” or “treatment” of a disease includes preventing the disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). For the purposes of this invention, a “disease” includes pain.
In certain embodiments, the subject methods, as described above, are methods of managing a disease condition, e.g., over an extended period of time, such as 1 week or longer, 1 month or longer, 6 months or longer, 1 year or longer, 2 years or longer, 5 years or longer, etc. The subject methods may be employed in conjunction with one or more additional disease management protocols, e.g., electrostimulation based protocols in cardiovascular disease management, such as pacing protocols, cardiac resynchronization protocols, etc; lifestyle, such a diet and/or exercise regimens for a variety of different disease conditions; etc.
In certain embodiments, the methods include modulating a therapeutic regimen based data obtained from the compositions. For example, data may be obtained which includes information about patient compliance with a prescribed therapeutic regimen. This data, with or without additional physiological data, e.g., obtained using one or more sensors, such as the sensor devices described above, may be employed, e.g., with appropriate decision tools as desired, to make determinations of whether a given treatment regimen should be maintained or modified in some way, e.g., by modification of a medication regimen and/or implant activity regimen. As such, methods of invention include methods in which a therapeutic regimen is modified based on signals obtained from the composition(s).
In certain embodiments, also provided are methods of determining the history of a composition of the invention, where the composition includes an active agent, an identifier element and a pharmaceutically acceptable carrier. In certain embodiments where the identifier emits a signal in response to an interrogation, the identifier is interrogated, e.g., by a wand or other suitable interrogation device, to obtain a signal. The obtained signal is then employed to determine historical information about the composition, e.g., source, chain of custody, etc.
In certain embodiments, a system is employed that is made up of a multiple different IEMs, e.g., 2 or more distinct IEMS, 3 or more distinct IEMS, 4 or more distinct IEMs, etc., including 5 or more, 7 or more, 10 or more distinct IEMs. The distinct IEMs may be configured to provide distinguishable signals, e.g., where the signals may be distinguishable in terms of nature of the signal itself, in terms of timing of emission of the signal, etc. For example, each IEM in such sets may emit a differently coded signal. Alternatively, each IEM may be configured to emit the signal at a different physiological target site, e.g., where each IEM is configured to be activated at a different target physiological site, e.g., where an first IEM is activated in the mouth, a second is activated in the esophagus, a third is activated in the small intestine and a fourth is activated in the large intestine. Such sets of multiple different distinguishable IEMs find use in a variety of different applications. For example, where one has the above described 4 IEM set, one can use the set in a diagnostic application to determine function of the digestive system, e.g., motility through the digestive tract, gastric emptying etc. For example, by noting when each IEM emits its respective signal, a plot of signal time may be generated from which information regarding digestive tract functioning may be obtained.
The present invention provides the clinician an important new tool in their therapeutic armamentarium: automatic detection and identification of pharmaceutical agents actually delivered into the body. The applications of this new information device and system are multi-fold. Applications include, but are not limited to: (1) monitoring patient compliance with prescribed therapeutic regimens; (2) tailoring therapeutic regimens based on patient compliance; (3) monitoring patient compliance in clinical trials; (4) monitoring usage of controlled substances; and the like. Each of these different illustrative applications is reviewed in greater detail below in copending PCT Application Serial No. PCT/US2006/016370; the disclosure of which is herein incorporated by reference.
Additional applications in which the subject systems find use include those described in U.S. Pat. No. 6,804,558, the disclosure of which is herein incorporated by reference. For example, the subject systems may be used in a medical information communication system which permits monitoring the performance of an implantable medical device (IMD) implanted within a body of a patient, monitoring the health of the patient, and/or remotely delivering a therapy to the patient through the IMD. A signal receiver of the invention, e.g., in an external format such as a bandaid or implanted format, communicates with the IMD and is capable of bidirectional communication with a communication module, a mobile telephone and/or a Personal Data Assistant (PDA) located outside the patient's body. The system may comprise the IMD, the signal receiver with the communication module and/or a mobile telephone and/or a PDA, a remote computer system, and a communication system capable of bidirectional communication, where the communication module, the mobile telephone and/or the PDA are capable of receiving information from the IMD or relaying information thereto via the signal receiver, which is internal or external to the patient, as reviewed above.
Additional applications in which receivers of the invention may find use include, but are not limited to: fertility monitoring, body fat monitoring, satiety monitoring, satiety control, total blood volume monitoring, cholesterol monitoring, smoking detection, etc.
Kits
Also provided are kits that include one or more in-body devices of the invention. Kits may include one or more in-body devices, e.g., as described above, including ingestible and/or implantable event markers. In those embodiments having a plurality of in-body devices (e.g. ingestible event markers), such may be packaged in a single container, e.g., a single tube, bottle, vial, and the like, or one or more dosage amounts may be individually packaged such that certain kits may have more than one container of an in-body device. In certain embodiments the kits may also include a signal receiving element, or receiver, as reviewed above. In certain embodiments, the kits may also include an external monitor device, e.g., as described above, which may provide for communication with a remote location, e.g., a doctor's office, a central facility etc., which obtains and processes data obtained about the usage of the composition.
The subject kits may also include instructions for how to practice the subject methods using the components of the kit. The instructions may be recorded on a suitable recording medium or substrate. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
Some or all components of the subject kits may be packaged in suitable packaging to maintain sterility. In many embodiments of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.
It is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
Certain ranges have been presented herein with numerical values being preceded by the term “about.” The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.
It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.
Pursuant to 35 U.S.C. §119 (e), this application claims priority to the filing date of U.S. Provisional Patent Application Ser. No. 60/894,171 filed on Mar. 9, 2007 and U.S. Provisional Patent Application Ser. No. 60/915,635 filed on May 2, 2007; the disclosures of which applications are herein incorporated by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2008/056296 | 3/7/2008 | WO | 00 | 9/8/2009 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2008/112577 | 9/18/2008 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3607788 | Adolph | Sep 1971 | A |
| 3628669 | McKinnis et al. | Dec 1971 | A |
| 3642008 | Bolduc | Feb 1972 | A |
| 3679480 | Brown et al. | Jul 1972 | A |
| 3682160 | Murata | Aug 1972 | A |
| 3719183 | Schwartz | Mar 1973 | A |
| 3828766 | Krasnow | Aug 1974 | A |
| 3837339 | Aisenberg et al. | Sep 1974 | A |
| 3893111 | Cotter | Jul 1975 | A |
| 3944064 | Bashaw et al. | Mar 1976 | A |
| 3967202 | Batz | Jun 1976 | A |
| 3989050 | Buchalter | Nov 1976 | A |
| 4017856 | Wiegand | Apr 1977 | A |
| 4055178 | Harrigan | Oct 1977 | A |
| 4062750 | Butler | Dec 1977 | A |
| 4077397 | Ellis | Mar 1978 | A |
| 4077398 | Ellis | Mar 1978 | A |
| 4082087 | Howson | Apr 1978 | A |
| 4090752 | Long | May 1978 | A |
| 4106348 | Auphan | Aug 1978 | A |
| 4129125 | Lester | Dec 1978 | A |
| 4166453 | McClelland | Sep 1979 | A |
| 4239046 | Ong | Dec 1980 | A |
| 4251795 | Shibasaki et al. | Feb 1981 | A |
| 4269189 | Abraham | May 1981 | A |
| 4331654 | Morris | May 1982 | A |
| 4345588 | Widder et al. | Aug 1982 | A |
| 4418697 | Tama | Dec 1983 | A |
| 4425117 | Hugemann et al. | Jan 1984 | A |
| 4439196 | Higuchi | Mar 1984 | A |
| 4494950 | Fischell | Jan 1985 | A |
| 4559950 | Vaughan | Dec 1985 | A |
| 4564363 | Bagnall et al. | Jan 1986 | A |
| 4635641 | Hoffman | Jan 1987 | A |
| 4654165 | Eisenberg | Mar 1987 | A |
| 4669479 | Dunseath | Jun 1987 | A |
| 4681111 | Silvian | Jul 1987 | A |
| 4687660 | Baker et al. | Aug 1987 | A |
| 4725997 | Urquhart et al. | Feb 1988 | A |
| 4763659 | Dunseath | Aug 1988 | A |
| 4784162 | Ricks | Nov 1988 | A |
| 4793825 | Benjamin et al. | Dec 1988 | A |
| 4844076 | Lesho | Jul 1989 | A |
| 4876093 | Theeuwes et al. | Oct 1989 | A |
| 4896261 | Nolan | Jan 1990 | A |
| 4975230 | Pinkhasov | Dec 1990 | A |
| 4987897 | Funke | Jan 1991 | A |
| 5000957 | Eckenhoff et al. | Mar 1991 | A |
| 5016634 | Vock et al. | May 1991 | A |
| 5079006 | Urquhart | Jan 1992 | A |
| 5167626 | Casper | Dec 1992 | A |
| 5176626 | Soehendra | Jan 1993 | A |
| 5245332 | Katzenstein et al. | Sep 1993 | A |
| 5261402 | DiSabito | Nov 1993 | A |
| 5263481 | Axelgaard et al. | Nov 1993 | A |
| 5279607 | Schentag et al. | Jan 1994 | A |
| 5281287 | Lloyd | Jan 1994 | A |
| 5283136 | Peled et al. | Feb 1994 | A |
| 5318557 | Gross | Jun 1994 | A |
| 5394882 | Mawhinney | Mar 1995 | A |
| 5395366 | D'Andrea et al. | Mar 1995 | A |
| 5458141 | Neil et al. | Oct 1995 | A |
| 5485841 | Watkin et al. | Jan 1996 | A |
| 5511548 | Riazzi et al. | Apr 1996 | A |
| 5567210 | Bates et al. | Oct 1996 | A |
| 5596302 | Mastrocola et al. | Jan 1997 | A |
| 5600548 | Nguyen et al. | Feb 1997 | A |
| 5634468 | Platt | Jun 1997 | A |
| 5645063 | Straka et al. | Jul 1997 | A |
| 5720771 | Snell | Feb 1998 | A |
| 5738708 | Peachey et al. | Apr 1998 | A |
| 5740811 | Hedberg | Apr 1998 | A |
| 5757326 | Koyama et al. | May 1998 | A |
| 5792048 | Schaefer | Aug 1998 | A |
| 5802467 | Salazar | Sep 1998 | A |
| 5833716 | Bar-Or | Nov 1998 | A |
| 5845265 | Woolston | Dec 1998 | A |
| 5862803 | Besson | Jan 1999 | A |
| 5868136 | Fox | Feb 1999 | A |
| 5921925 | Cartmell et al. | Jul 1999 | A |
| 5925030 | Gross et al. | Jul 1999 | A |
| 5957854 | Besson | Sep 1999 | A |
| 5963132 | Yoakum et al. | Oct 1999 | A |
| 5974124 | Schlueter, Jr. et al. | Oct 1999 | A |
| 5999846 | Pardey et al. | Dec 1999 | A |
| 6023631 | Cartmell et al. | Feb 2000 | A |
| 6038464 | Axelgaard et al. | Mar 2000 | A |
| 6042710 | Dubrow | Mar 2000 | A |
| 6047203 | Sackner | Apr 2000 | A |
| 6076016 | Feierbach et al. | Jun 2000 | A |
| 6081734 | Batz | Jun 2000 | A |
| 6090489 | Hayakawa et al. | Jul 2000 | A |
| 6095985 | Raymond et al. | Aug 2000 | A |
| 6122351 | Schlueter, Jr. et al. | Sep 2000 | A |
| 6141592 | Pauly | Oct 2000 | A |
| 6149940 | Maggi et al. | Nov 2000 | A |
| 6200265 | Walsh et al. | Mar 2001 | B1 |
| 6204764 | Maloney | Mar 2001 | B1 |
| 6206702 | Hayden et al. | Mar 2001 | B1 |
| 6217744 | Crosby | Apr 2001 | B1 |
| 6231593 | Meserol | May 2001 | B1 |
| 6245057 | Sieben et al. | Jun 2001 | B1 |
| 6269058 | Yamanoi et al. | Jul 2001 | B1 |
| 6275476 | Wood | Aug 2001 | B1 |
| 6285897 | Kilcoyne et al. | Sep 2001 | B1 |
| 6287252 | Lugo | Sep 2001 | B1 |
| 6288629 | Cofino et al. | Sep 2001 | B1 |
| 6289238 | Besson | Sep 2001 | B1 |
| 6315719 | Rode et al. | Nov 2001 | B1 |
| 6358202 | Arent | Mar 2002 | B1 |
| 6364834 | Reuss | Apr 2002 | B1 |
| 6366206 | Ishikawa et al. | Apr 2002 | B1 |
| 6371927 | Brune | Apr 2002 | B1 |
| 6374670 | Spelman | Apr 2002 | B1 |
| 6380858 | Yarin et al. | Apr 2002 | B1 |
| 6390088 | Nohl et al. | May 2002 | B1 |
| 6394997 | Lemelson | May 2002 | B1 |
| 6409674 | Brockway et al. | Jun 2002 | B1 |
| 6426863 | Munshi | Jul 2002 | B1 |
| 6432292 | Pinto et al. | Aug 2002 | B1 |
| 6440069 | Raymond et al. | Aug 2002 | B1 |
| 6441747 | Khair | Aug 2002 | B1 |
| 6453199 | Kobozev | Sep 2002 | B1 |
| 6477424 | Thompson et al. | Nov 2002 | B1 |
| 6482156 | Lliff | Nov 2002 | B2 |
| 6496705 | Ng et al. | Dec 2002 | B1 |
| 6526315 | Inagawa | Feb 2003 | B1 |
| 6544174 | West | Apr 2003 | B2 |
| 6564079 | Cory | May 2003 | B1 |
| 6577893 | Besson | Jun 2003 | B1 |
| 6579231 | Phipps | Jun 2003 | B1 |
| 6599284 | Faour et al. | Jul 2003 | B2 |
| 6609018 | Cory | Aug 2003 | B2 |
| 6612984 | Kerr | Sep 2003 | B1 |
| 6632175 | Marshall | Oct 2003 | B1 |
| 6632216 | Houzego et al. | Oct 2003 | B2 |
| 6643541 | Mok et al. | Nov 2003 | B2 |
| 6654638 | Sweeney | Nov 2003 | B1 |
| 6663846 | McCombs | Dec 2003 | B1 |
| 6673474 | Yamamoto | Jan 2004 | B2 |
| 6680923 | Leon | Jan 2004 | B1 |
| 6689117 | Sweeney et al. | Feb 2004 | B2 |
| 6694161 | Mehrotra | Feb 2004 | B2 |
| 6704602 | Berg et al. | Mar 2004 | B2 |
| 6720923 | Hayward et al. | Apr 2004 | B1 |
| 6738671 | Christophersom et al. | May 2004 | B2 |
| 6740033 | Olejniczak et al. | May 2004 | B1 |
| 6745082 | Axelgaard et al. | Jun 2004 | B2 |
| 6755783 | Cosentino | Jun 2004 | B2 |
| 6757523 | Fry | Jun 2004 | B2 |
| 6773429 | Sheppard et al. | Aug 2004 | B2 |
| 6800060 | Marshall | Oct 2004 | B2 |
| 6801137 | Eggers et al. | Oct 2004 | B2 |
| 6822554 | Vrijens et al. | Nov 2004 | B2 |
| 6836862 | Erekson et al. | Dec 2004 | B1 |
| 6839659 | Tarassenko et al. | Jan 2005 | B2 |
| 6840904 | Goldberg | Jan 2005 | B2 |
| 6842636 | Perrault | Jan 2005 | B2 |
| 6845272 | Thomsen | Jan 2005 | B1 |
| 6864780 | Doi | Mar 2005 | B2 |
| 6879810 | Bouet | Apr 2005 | B2 |
| 6909878 | Haller | Jun 2005 | B2 |
| 6922592 | Thompson et al. | Jul 2005 | B2 |
| 6928370 | Anuzis et al. | Aug 2005 | B2 |
| 6929636 | von Alten | Aug 2005 | B1 |
| 6937150 | Medema | Aug 2005 | B2 |
| 6942616 | Kerr | Sep 2005 | B2 |
| 6951536 | Yokoi | Oct 2005 | B2 |
| 6957107 | Rogers et al. | Oct 2005 | B2 |
| 6968153 | Heinonen | Nov 2005 | B1 |
| 6987965 | Ng et al. | Jan 2006 | B2 |
| 6990082 | Zehavi et al. | Jan 2006 | B1 |
| 7002476 | Rapchak | Feb 2006 | B2 |
| 7004395 | Koenck | Feb 2006 | B2 |
| 7009634 | Iddan et al. | Mar 2006 | B2 |
| 7009946 | Kardach | Mar 2006 | B1 |
| 7013162 | Gorsuch | Mar 2006 | B2 |
| 7016648 | Haller | Mar 2006 | B2 |
| 7020508 | Stivoric | Mar 2006 | B2 |
| 7024248 | Penner et al. | Apr 2006 | B2 |
| 7031745 | Shen | Apr 2006 | B2 |
| 7031857 | Tarassenko et al. | Apr 2006 | B2 |
| 7039453 | Mullick | May 2006 | B2 |
| 7046649 | Awater et al. | May 2006 | B2 |
| 7076437 | Levy | Jul 2006 | B1 |
| 7118531 | Krill | Oct 2006 | B2 |
| 7127300 | Mazar et al. | Oct 2006 | B2 |
| 7146228 | Nielsen | Dec 2006 | B2 |
| 7146449 | Do et al. | Dec 2006 | B2 |
| 7149581 | Goedeke et al. | Dec 2006 | B2 |
| 7154071 | Sattler et al. | Dec 2006 | B2 |
| 7155232 | Godfrey et al. | Dec 2006 | B2 |
| 7160258 | Imran | Jan 2007 | B2 |
| 7164942 | Avrahami | Jan 2007 | B2 |
| 7171166 | Ng et al. | Jan 2007 | B2 |
| 7171177 | Park et al. | Jan 2007 | B2 |
| 7171259 | Rytky | Jan 2007 | B2 |
| 7176784 | Gilbert et al. | Feb 2007 | B2 |
| 7187960 | Abreu | Mar 2007 | B2 |
| 7188767 | Penuela | Mar 2007 | B2 |
| 7194038 | Inkinen | Mar 2007 | B1 |
| 7206630 | Tarler | Apr 2007 | B1 |
| 7209790 | Thompson et al. | Apr 2007 | B2 |
| 7215660 | Perlman | May 2007 | B2 |
| 7215991 | Besson | May 2007 | B2 |
| 7218967 | Bergelson | May 2007 | B2 |
| 7231451 | Law | Jun 2007 | B2 |
| 7243118 | Lou | Jul 2007 | B2 |
| 7246521 | Kim | Jul 2007 | B2 |
| 7249212 | Do | Jul 2007 | B2 |
| 7252792 | Perrault | Aug 2007 | B2 |
| 7253716 | Lovoi et al. | Aug 2007 | B2 |
| 7261690 | Teller | Aug 2007 | B2 |
| 7270633 | Goscha | Sep 2007 | B1 |
| 7273454 | Raymond et al. | Sep 2007 | B2 |
| 7289855 | Nghiem | Oct 2007 | B2 |
| 7291497 | Holmes | Nov 2007 | B2 |
| 7292139 | Mazar et al. | Nov 2007 | B2 |
| 7294105 | Islam | Nov 2007 | B1 |
| 7313163 | Liu | Dec 2007 | B2 |
| 7317378 | Jarvis et al. | Jan 2008 | B2 |
| 7318808 | Tarassenko et al. | Jan 2008 | B2 |
| 7336929 | Yasuda | Feb 2008 | B2 |
| 7342895 | Serpa | Mar 2008 | B2 |
| 7346380 | Axelgaard et al. | Mar 2008 | B2 |
| 7349722 | Witkowski et al. | Mar 2008 | B2 |
| 7352998 | Palin | Apr 2008 | B2 |
| 7353258 | Washburn | Apr 2008 | B2 |
| 7357891 | Yang et al. | Apr 2008 | B2 |
| 7359674 | Markki | Apr 2008 | B2 |
| 7366558 | Virtanen et al. | Apr 2008 | B2 |
| 7368190 | Heller et al. | May 2008 | B2 |
| 7368191 | Andelman et al. | May 2008 | B2 |
| 7373196 | Ryu et al. | May 2008 | B2 |
| 7375739 | Robbins | May 2008 | B2 |
| 7376435 | McGowan | May 2008 | B2 |
| 7382263 | Danowski et al. | Jun 2008 | B2 |
| 7387607 | Holt | Jun 2008 | B2 |
| 7388903 | Godfrey et al. | Jun 2008 | B2 |
| 7389088 | Kim | Jun 2008 | B2 |
| 7392015 | Farlow | Jun 2008 | B1 |
| 7395106 | Ryu et al. | Jul 2008 | B2 |
| 7396330 | Banet | Jul 2008 | B2 |
| 7404968 | Abrams et al. | Jul 2008 | B2 |
| 7413544 | Kerr | Aug 2008 | B2 |
| 7414534 | Kroll et al. | Aug 2008 | B1 |
| 7414543 | Rye et al. | Aug 2008 | B2 |
| 7415242 | Ngan | Aug 2008 | B1 |
| 7424268 | Diener | Sep 2008 | B2 |
| 7424319 | Muehlsteff | Sep 2008 | B2 |
| 7427266 | Ayer et al. | Sep 2008 | B2 |
| 7471665 | Perlman | Dec 2008 | B2 |
| 7499674 | Salokannel | Mar 2009 | B2 |
| 7502643 | Farringdon et al. | Mar 2009 | B2 |
| 7510121 | Koenck | Mar 2009 | B2 |
| 7512448 | Malick | Mar 2009 | B2 |
| 7515043 | Welch | Apr 2009 | B2 |
| 7519416 | Sula et al. | Apr 2009 | B2 |
| 7523756 | Minai | Apr 2009 | B2 |
| 7525426 | Edelstein | Apr 2009 | B2 |
| 7539533 | Tran | May 2009 | B2 |
| 7542878 | Nanikashvili | Jun 2009 | B2 |
| 7551590 | Haller | Jun 2009 | B2 |
| 7554452 | Cole | Jun 2009 | B2 |
| 7558620 | Ishibashi | Jul 2009 | B2 |
| 7575005 | Mumford | Aug 2009 | B2 |
| 7616111 | Covannon | Nov 2009 | B2 |
| 7616710 | Kim et al. | Nov 2009 | B2 |
| 7617001 | Penner et al. | Nov 2009 | B2 |
| 7639473 | Hsu et al. | Dec 2009 | B2 |
| 7640802 | King et al. | Jan 2010 | B2 |
| 7647112 | Tracey | Jan 2010 | B2 |
| 7647185 | Tarassenko et al. | Jan 2010 | B2 |
| 7653031 | Godfrey et al. | Jan 2010 | B2 |
| 7672714 | Kuo | Mar 2010 | B2 |
| 7673679 | Harrison et al. | Mar 2010 | B2 |
| 7678043 | Gilad | Mar 2010 | B2 |
| 7697994 | VanDanacker et al. | Apr 2010 | B2 |
| 7720036 | Sadri | May 2010 | B2 |
| 7729776 | Von Arx et al. | Jun 2010 | B2 |
| 7733224 | Tran | Jun 2010 | B2 |
| 7736318 | Costentino | Jun 2010 | B2 |
| 7756587 | Penner et al. | Jul 2010 | B2 |
| 7779614 | McGonagle et al. | Aug 2010 | B1 |
| 7796043 | Euliano et al. | Sep 2010 | B2 |
| 7797033 | D'Andrea et al. | Sep 2010 | B2 |
| 7809399 | Lu | Oct 2010 | B2 |
| 7844341 | Von Arx et al. | Nov 2010 | B2 |
| 7904133 | Gehman et al. | Mar 2011 | B2 |
| 8025149 | Sterry et al. | Sep 2011 | B2 |
| 8073707 | Teller et al. | Dec 2011 | B2 |
| 8083128 | Dembo et al. | Dec 2011 | B2 |
| 8123576 | Kim | Feb 2012 | B2 |
| 8180425 | Selvitelli et al. | May 2012 | B2 |
| 8200320 | Kovacs | Jun 2012 | B2 |
| 8214007 | Baker et al. | Jul 2012 | B2 |
| 8238998 | Park | Aug 2012 | B2 |
| 8249686 | Libbus et al. | Aug 2012 | B2 |
| 8258962 | Robertson et al. | Sep 2012 | B2 |
| 8285356 | Bly et al. | Oct 2012 | B2 |
| 8290574 | Felid et al. | Oct 2012 | B2 |
| 8301232 | Albert et al. | Oct 2012 | B2 |
| 8308640 | Baldus et al. | Nov 2012 | B2 |
| 8315687 | Cross et al. | Nov 2012 | B2 |
| 8369936 | Farringdon et al. | Feb 2013 | B2 |
| 8386009 | Lindberg et al. | Feb 2013 | B2 |
| 8389003 | Mintchev et al. | Mar 2013 | B2 |
| 8597186 | Hafezi et al. | Dec 2013 | B2 |
| 20010027331 | Thompson | Oct 2001 | A1 |
| 20010031071 | Nichols et al. | Oct 2001 | A1 |
| 20010044588 | Mault | Nov 2001 | A1 |
| 20010051766 | Gazdzinski et al. | Dec 2001 | A1 |
| 20020002326 | Causey, III | Jan 2002 | A1 |
| 20020026111 | Ackerman | Feb 2002 | A1 |
| 20020032384 | Raymond et al. | Mar 2002 | A1 |
| 20020032385 | Raymond et al. | Mar 2002 | A1 |
| 20020040278 | Anuzis et al. | Apr 2002 | A1 |
| 20020077620 | Sweeney et al. | Jun 2002 | A1 |
| 20020132226 | Nair | Sep 2002 | A1 |
| 20020138009 | Brockway et al. | Sep 2002 | A1 |
| 20020193669 | Glukhovsky | Dec 2002 | A1 |
| 20020193846 | Pool et al. | Dec 2002 | A1 |
| 20030017826 | Fishman | Jan 2003 | A1 |
| 20030023150 | Yokoi et al. | Jan 2003 | A1 |
| 20030028226 | Thompson | Feb 2003 | A1 |
| 20030063522 | Sagar | Apr 2003 | A1 |
| 20030065536 | Hansen | Apr 2003 | A1 |
| 20030083559 | Thompson | May 2003 | A1 |
| 20030126593 | Mault | Jul 2003 | A1 |
| 20030130714 | Nielsen et al. | Jul 2003 | A1 |
| 20030135128 | Suffin et al. | Jul 2003 | A1 |
| 20030135392 | Vrijens et al. | Jul 2003 | A1 |
| 20030152622 | Louie-Helm et al. | Aug 2003 | A1 |
| 20030158466 | Lynn et al. | Aug 2003 | A1 |
| 20030158756 | Abramson | Aug 2003 | A1 |
| 20030162556 | Libes | Aug 2003 | A1 |
| 20030167000 | Mullick et al. | Sep 2003 | A1 |
| 20030171791 | KenKnight | Sep 2003 | A1 |
| 20030171898 | Tarassenko et al. | Sep 2003 | A1 |
| 20030181788 | Yokoi et al. | Sep 2003 | A1 |
| 20030181815 | Ebner et al. | Sep 2003 | A1 |
| 20030185286 | Yuen | Oct 2003 | A1 |
| 20030187337 | Tarassenko et al. | Oct 2003 | A1 |
| 20030187338 | Say et al. | Oct 2003 | A1 |
| 20030195403 | Berner et al. | Oct 2003 | A1 |
| 20030213495 | Fujita et al. | Nov 2003 | A1 |
| 20030214579 | Iddan | Nov 2003 | A1 |
| 20030216622 | Meron et al. | Nov 2003 | A1 |
| 20030216625 | Phipps | Nov 2003 | A1 |
| 20030216666 | Ericson et al. | Nov 2003 | A1 |
| 20030216729 | Marchitto | Nov 2003 | A1 |
| 20030229382 | Sun et al. | Dec 2003 | A1 |
| 20030232895 | Omidian et al. | Dec 2003 | A1 |
| 20040008123 | Carrender et al. | Jan 2004 | A1 |
| 20040018476 | LaDue | Jan 2004 | A1 |
| 20040019172 | Yang et al. | Jan 2004 | A1 |
| 20040034295 | Salganicoff | Feb 2004 | A1 |
| 20040049245 | Gass | Mar 2004 | A1 |
| 20040073095 | Causey et al. | Apr 2004 | A1 |
| 20040073454 | Urquhart et al. | Apr 2004 | A1 |
| 20040077995 | Ferek-Petric | Apr 2004 | A1 |
| 20040082982 | Gord et al. | Apr 2004 | A1 |
| 20040087839 | Raymond et al. | May 2004 | A1 |
| 20040092801 | Drakulic | May 2004 | A1 |
| 20040106859 | Say et al. | Jun 2004 | A1 |
| 20040111011 | Uchiyama et al. | Jun 2004 | A1 |
| 20040115517 | Fukuda et al. | Jun 2004 | A1 |
| 20040121015 | Chidlaw et al. | Jun 2004 | A1 |
| 20040122297 | Stahmann et al. | Jun 2004 | A1 |
| 20040148140 | Tarassenko et al. | Jul 2004 | A1 |
| 20040153007 | Harris | Aug 2004 | A1 |
| 20040167226 | Serafini | Aug 2004 | A1 |
| 20040167801 | Say et al. | Aug 2004 | A1 |
| 20040171914 | Avni | Sep 2004 | A1 |
| 20040193020 | Chiba | Sep 2004 | A1 |
| 20040193029 | Gluhovsky | Sep 2004 | A1 |
| 20040193446 | Mayer et al. | Sep 2004 | A1 |
| 20040199222 | Sun et al. | Oct 2004 | A1 |
| 20040215084 | Shimizu et al. | Oct 2004 | A1 |
| 20040218683 | Batra | Nov 2004 | A1 |
| 20040220643 | Schmidt | Nov 2004 | A1 |
| 20040224644 | Wu | Nov 2004 | A1 |
| 20040225199 | Evanyk | Nov 2004 | A1 |
| 20040253304 | Gross et al. | Dec 2004 | A1 |
| 20040258571 | Lee et al. | Dec 2004 | A1 |
| 20040260154 | Sidelnik | Dec 2004 | A1 |
| 20040267240 | Gross et al. | Dec 2004 | A1 |
| 20050017841 | Doi | Jan 2005 | A1 |
| 20050020887 | Goldberg | Jan 2005 | A1 |
| 20050021370 | Riff | Jan 2005 | A1 |
| 20050024198 | Ward | Feb 2005 | A1 |
| 20050027205 | Tarassenko et al. | Feb 2005 | A1 |
| 20050038321 | Fujita et al. | Feb 2005 | A1 |
| 20050043634 | Yokoi et al. | Feb 2005 | A1 |
| 20050054897 | Hashimoto et al. | Mar 2005 | A1 |
| 20050055014 | Coppeta et al. | Mar 2005 | A1 |
| 20050062644 | Leci | Mar 2005 | A1 |
| 20050065407 | Nakamura et al. | Mar 2005 | A1 |
| 20050070778 | Lackey | Mar 2005 | A1 |
| 20050092108 | Andermo | May 2005 | A1 |
| 20050096514 | Starkebaum | May 2005 | A1 |
| 20050096562 | Delalic et al. | May 2005 | A1 |
| 20050101843 | Quinn | May 2005 | A1 |
| 20050101872 | Sattler | May 2005 | A1 |
| 20050115561 | Stahmann et al. | Jun 2005 | A1 |
| 20050116820 | Goldreich | Jun 2005 | A1 |
| 20050117389 | Worledge | Jun 2005 | A1 |
| 20050121322 | Say et al. | Jun 2005 | A1 |
| 20050131281 | Ayer et al. | Jun 2005 | A1 |
| 20050143623 | Kojima | Jun 2005 | A1 |
| 20050146594 | Nakatani et al. | Jul 2005 | A1 |
| 20050148883 | Boesen | Jul 2005 | A1 |
| 20050151625 | Lai | Jul 2005 | A1 |
| 20050154428 | Bruinsma | Jul 2005 | A1 |
| 20050165323 | Montgomery | Jul 2005 | A1 |
| 20050177069 | Takizawa | Aug 2005 | A1 |
| 20050182389 | LaPorte | Aug 2005 | A1 |
| 20050187789 | Hatlestad et al. | Aug 2005 | A1 |
| 20050192489 | Marshall | Sep 2005 | A1 |
| 20050197680 | DelMain et al. | Sep 2005 | A1 |
| 20050228268 | Cole | Oct 2005 | A1 |
| 20050234307 | Heinonen | Oct 2005 | A1 |
| 20050240305 | Bogash et al. | Oct 2005 | A1 |
| 20050245794 | Dinsmoor | Nov 2005 | A1 |
| 20050245839 | Stivoric et al. | Nov 2005 | A1 |
| 20050259768 | Yang et al. | Nov 2005 | A1 |
| 20050261559 | Mumford | Nov 2005 | A1 |
| 20050267556 | Shuros et al. | Dec 2005 | A1 |
| 20050267756 | Schultz et al. | Dec 2005 | A1 |
| 20050277912 | John | Dec 2005 | A1 |
| 20050277999 | Strother et al. | Dec 2005 | A1 |
| 20050285746 | Sengupta | Dec 2005 | A1 |
| 20050288594 | Lewkowicz et al. | Dec 2005 | A1 |
| 20060001496 | Abrosimov et al. | Jan 2006 | A1 |
| 20060028727 | Moon et al. | Feb 2006 | A1 |
| 20060036134 | Tarassenko et al. | Feb 2006 | A1 |
| 20060061472 | Lovoi et al. | Mar 2006 | A1 |
| 20060065713 | Kingery | Mar 2006 | A1 |
| 20060068006 | Begleiter | Mar 2006 | A1 |
| 20060074283 | Henderson | Apr 2006 | A1 |
| 20060074319 | Barnes et al. | Apr 2006 | A1 |
| 20060078765 | Yang et al. | Apr 2006 | A1 |
| 20060095091 | Drew | May 2006 | A1 |
| 20060095093 | Bettesh et al. | May 2006 | A1 |
| 20060100533 | Han | May 2006 | A1 |
| 20060109058 | Keating | May 2006 | A1 |
| 20060110962 | Powell | May 2006 | A1 |
| 20060122667 | Chavan et al. | Jun 2006 | A1 |
| 20060136266 | Tarassenko et al. | Jun 2006 | A1 |
| 20060142648 | Banet | Jun 2006 | A1 |
| 20060145876 | Kimura | Jul 2006 | A1 |
| 20060148254 | McLean | Jul 2006 | A1 |
| 20060149339 | Burnes | Jul 2006 | A1 |
| 20060155174 | Glukhovsky et al. | Jul 2006 | A1 |
| 20060155183 | Kroecker | Jul 2006 | A1 |
| 20060158820 | Takiguchi | Jul 2006 | A1 |
| 20060161225 | Sormann et al. | Jul 2006 | A1 |
| 20060169292 | Iddan | Aug 2006 | A1 |
| 20060179949 | Kim | Aug 2006 | A1 |
| 20060183992 | Kawashima | Aug 2006 | A1 |
| 20060183993 | Horn | Aug 2006 | A1 |
| 20060184092 | Atanasoska et al. | Aug 2006 | A1 |
| 20060204738 | Dubrow et al. | Sep 2006 | A1 |
| 20060210626 | Spaeder | Sep 2006 | A1 |
| 20060216603 | Choi | Sep 2006 | A1 |
| 20060218011 | Walker | Sep 2006 | A1 |
| 20060229053 | Sivard | Oct 2006 | A1 |
| 20060235489 | Drew | Oct 2006 | A1 |
| 20060243288 | Kim et al. | Nov 2006 | A1 |
| 20060247505 | Siddiqui | Nov 2006 | A1 |
| 20060253005 | Drinan | Nov 2006 | A1 |
| 20060255064 | Donaldson | Nov 2006 | A1 |
| 20060265246 | Hoag | Nov 2006 | A1 |
| 20060267774 | Feinberg et al. | Nov 2006 | A1 |
| 20060270346 | Ibrahim | Nov 2006 | A1 |
| 20060273882 | Posamentier | Dec 2006 | A1 |
| 20060280227 | Pinkney | Dec 2006 | A1 |
| 20060280277 | Pinkney | Dec 2006 | A1 |
| 20060282001 | Noel | Dec 2006 | A1 |
| 20060289640 | Mercure | Dec 2006 | A1 |
| 20060293607 | Alt | Dec 2006 | A1 |
| 20070000776 | Karube et al. | Jan 2007 | A1 |
| 20070002038 | Suzuki | Jan 2007 | A1 |
| 20070006636 | King et al. | Jan 2007 | A1 |
| 20070008113 | Spoonhower et al. | Jan 2007 | A1 |
| 20070016089 | Fischell et al. | Jan 2007 | A1 |
| 20070027386 | Such | Feb 2007 | A1 |
| 20070027388 | Chou | Feb 2007 | A1 |
| 20070038054 | Zhou | Feb 2007 | A1 |
| 20070049339 | Barak et al. | Mar 2007 | A1 |
| 20070055098 | Shimizu et al. | Mar 2007 | A1 |
| 20070060797 | Ball | Mar 2007 | A1 |
| 20070066929 | Ferren et al. | Mar 2007 | A1 |
| 20070073353 | Rooney et al. | Mar 2007 | A1 |
| 20070096765 | Kagan | May 2007 | A1 |
| 20070106346 | Bergelson | May 2007 | A1 |
| 20070123772 | Euliano | May 2007 | A1 |
| 20070129622 | Bourget | Jun 2007 | A1 |
| 20070130287 | Kumar | Jun 2007 | A1 |
| 20070135691 | Zingelewicz et al. | Jun 2007 | A1 |
| 20070135803 | Belson | Jun 2007 | A1 |
| 20070142721 | Berner et al. | Jun 2007 | A1 |
| 20070156016 | Betesh | Jul 2007 | A1 |
| 20070160789 | Merical | Jul 2007 | A1 |
| 20070162089 | Mosesov | Jul 2007 | A1 |
| 20070162090 | Penner | Jul 2007 | A1 |
| 20070167495 | Brown et al. | Jul 2007 | A1 |
| 20070167848 | Kuo et al. | Jul 2007 | A1 |
| 20070173701 | Al-Ali | Jul 2007 | A1 |
| 20070179347 | Tarassenko et al. | Aug 2007 | A1 |
| 20070180047 | Dong et al. | Aug 2007 | A1 |
| 20070185393 | Zhou | Aug 2007 | A1 |
| 20070191002 | Ge | Aug 2007 | A1 |
| 20070196456 | Stevens | Aug 2007 | A1 |
| 20070207793 | Myer | Sep 2007 | A1 |
| 20070207858 | Breving | Sep 2007 | A1 |
| 20070208233 | Kovacs | Sep 2007 | A1 |
| 20070213659 | Trovato et al. | Sep 2007 | A1 |
| 20070237719 | Jones | Oct 2007 | A1 |
| 20070244370 | Kuo et al. | Oct 2007 | A1 |
| 20070255198 | Leong et al. | Nov 2007 | A1 |
| 20070255330 | Lee | Nov 2007 | A1 |
| 20070270672 | Hayter | Nov 2007 | A1 |
| 20070279217 | Venkatraman | Dec 2007 | A1 |
| 20070282174 | Sabatino | Dec 2007 | A1 |
| 20070282177 | Pilz | Dec 2007 | A1 |
| 20070299480 | Hill | Dec 2007 | A1 |
| 20080014866 | Lipowshi | Jan 2008 | A1 |
| 20080015421 | Penner | Jan 2008 | A1 |
| 20080015494 | Santini et al. | Jan 2008 | A1 |
| 20080020037 | Robertson et al. | Jan 2008 | A1 |
| 20080021519 | DeGeest | Jan 2008 | A1 |
| 20080021521 | Shah | Jan 2008 | A1 |
| 20080027679 | Shklarski | Jan 2008 | A1 |
| 20080033273 | Zhou | Feb 2008 | A1 |
| 20080038588 | Lee | Feb 2008 | A1 |
| 20080039700 | Drinan et al. | Feb 2008 | A1 |
| 20080046038 | Hill | Feb 2008 | A1 |
| 20080051667 | Goldreich | Feb 2008 | A1 |
| 20080051767 | Rossing et al. | Feb 2008 | A1 |
| 20080058614 | Banet | Mar 2008 | A1 |
| 20080062856 | Feher | Mar 2008 | A1 |
| 20080065168 | Bitton et al. | Mar 2008 | A1 |
| 20080074307 | Boric-Lubecke | Mar 2008 | A1 |
| 20080077015 | Botic-Lubecke | Mar 2008 | A1 |
| 20080077188 | Denker et al. | Mar 2008 | A1 |
| 20080091089 | Guillory et al. | Apr 2008 | A1 |
| 20080091114 | Min | Apr 2008 | A1 |
| 20080097549 | Colbaugh | Apr 2008 | A1 |
| 20080097917 | Dicks | Apr 2008 | A1 |
| 20080099366 | Niemic et al. | May 2008 | A1 |
| 20080103440 | Ferren et al. | May 2008 | A1 |
| 20080114224 | Bandy et al. | May 2008 | A1 |
| 20080119705 | Patel | May 2008 | A1 |
| 20080119716 | Boric-Lubecke | May 2008 | A1 |
| 20080121825 | Trovato et al. | May 2008 | A1 |
| 20080137566 | Marholev | Jun 2008 | A1 |
| 20080139907 | Rao et al. | Jun 2008 | A1 |
| 20080140403 | Hughes et al. | Jun 2008 | A1 |
| 20080146871 | Arneson et al. | Jun 2008 | A1 |
| 20080146889 | Young | Jun 2008 | A1 |
| 20080146892 | LeBoeuf | Jun 2008 | A1 |
| 20080154104 | Lamego | Jun 2008 | A1 |
| 20080166992 | Ricordi | Jul 2008 | A1 |
| 20080175898 | Jones et al. | Jul 2008 | A1 |
| 20080183245 | Van Oort | Jul 2008 | A1 |
| 20080188837 | Belsky et al. | Aug 2008 | A1 |
| 20080194912 | Trovato et al. | Aug 2008 | A1 |
| 20080208009 | Shklarski | Aug 2008 | A1 |
| 20080214901 | Gehman | Sep 2008 | A1 |
| 20080214985 | Yanaki | Sep 2008 | A1 |
| 20080223936 | Mickle et al. | Sep 2008 | A1 |
| 20080243020 | Chou | Oct 2008 | A1 |
| 20080249360 | Li | Oct 2008 | A1 |
| 20080262320 | Schaefer et al. | Oct 2008 | A1 |
| 20080262336 | Ryu | Oct 2008 | A1 |
| 20080269664 | Trovato et al. | Oct 2008 | A1 |
| 20080275312 | Mosesov | Nov 2008 | A1 |
| 20080281636 | Jung et al. | Nov 2008 | A1 |
| 20080284599 | Zdeblick et al. | Nov 2008 | A1 |
| 20080288026 | Cross et al. | Nov 2008 | A1 |
| 20080288027 | Kroll | Nov 2008 | A1 |
| 20080294020 | Sapounas | Nov 2008 | A1 |
| 20080299197 | Toneguzzo et al. | Dec 2008 | A1 |
| 20080300572 | Rankers | Dec 2008 | A1 |
| 20080303638 | Nguyen | Dec 2008 | A1 |
| 20080306357 | Korman | Dec 2008 | A1 |
| 20080306359 | Zdeblick et al. | Dec 2008 | A1 |
| 20080306360 | Robertson et al. | Dec 2008 | A1 |
| 20080306362 | Davis | Dec 2008 | A1 |
| 20080311852 | Hansen | Dec 2008 | A1 |
| 20080312522 | Rowlandson | Dec 2008 | A1 |
| 20080316020 | Robertson | Dec 2008 | A1 |
| 20090009332 | Nunez et al. | Jan 2009 | A1 |
| 20090024045 | Prakash | Jan 2009 | A1 |
| 20090024112 | Edwards et al. | Jan 2009 | A1 |
| 20090030293 | Cooper et al. | Jan 2009 | A1 |
| 20090030297 | Miller | Jan 2009 | A1 |
| 20090034209 | Joo | Feb 2009 | A1 |
| 20090043171 | Rule | Feb 2009 | A1 |
| 20090048498 | Riskey | Feb 2009 | A1 |
| 20090062634 | Say et al. | Mar 2009 | A1 |
| 20090062670 | Sterling | Mar 2009 | A1 |
| 20090069642 | Gao | Mar 2009 | A1 |
| 20090069655 | Say et al. | Mar 2009 | A1 |
| 20090069656 | Say et al. | Mar 2009 | A1 |
| 20090069657 | Say et al. | Mar 2009 | A1 |
| 20090069658 | Say et al. | Mar 2009 | A1 |
| 20090076340 | Libbus et al. | Mar 2009 | A1 |
| 20090076343 | James | Mar 2009 | A1 |
| 20090076397 | Libbus et al. | Mar 2009 | A1 |
| 20090082645 | Hafezi et al. | Mar 2009 | A1 |
| 20090087483 | Sison | Apr 2009 | A1 |
| 20090088618 | Ameson | Apr 2009 | A1 |
| 20090099435 | Say et al. | Apr 2009 | A1 |
| 20090105561 | Boydon et al. | Apr 2009 | A1 |
| 20090110148 | Zhang | Apr 2009 | A1 |
| 20090112626 | Talbot | Apr 2009 | A1 |
| 20090124871 | Arshak | May 2009 | A1 |
| 20090131774 | Sweitzer | May 2009 | A1 |
| 20090135886 | Robertson et al. | May 2009 | A1 |
| 20090142853 | Warrington et al. | Jun 2009 | A1 |
| 20090157113 | Marcotte | Jun 2009 | A1 |
| 20090157358 | Kim | Jun 2009 | A1 |
| 20090161602 | Matsumoto | Jun 2009 | A1 |
| 20090163789 | Say et al. | Jun 2009 | A1 |
| 20090171180 | Pering | Jul 2009 | A1 |
| 20090173628 | Say et al. | Jul 2009 | A1 |
| 20090177055 | Say et al. | Jul 2009 | A1 |
| 20090177056 | Say et al. | Jul 2009 | A1 |
| 20090177057 | Say et al. | Jul 2009 | A1 |
| 20090177058 | Say et al. | Jul 2009 | A1 |
| 20090177059 | Say et al. | Jul 2009 | A1 |
| 20090177060 | Say et al. | Jul 2009 | A1 |
| 20090177061 | Say et al. | Jul 2009 | A1 |
| 20090177062 | Say et al. | Jul 2009 | A1 |
| 20090177063 | Say et al. | Jul 2009 | A1 |
| 20090177064 | Say et al. | Jul 2009 | A1 |
| 20090177065 | Say et al. | Jul 2009 | A1 |
| 20090177066 | Say et al. | Jul 2009 | A1 |
| 20090182206 | Najafi | Jul 2009 | A1 |
| 20090182207 | Riskey et al. | Jul 2009 | A1 |
| 20090182212 | Say et al. | Jul 2009 | A1 |
| 20090182213 | Say et al. | Jul 2009 | A1 |
| 20090182214 | Say et al. | Jul 2009 | A1 |
| 20090182215 | Say et al. | Jul 2009 | A1 |
| 20090182388 | Von Arx | Jul 2009 | A1 |
| 20090187088 | Say et al. | Jul 2009 | A1 |
| 20090187089 | Say et al. | Jul 2009 | A1 |
| 20090187090 | Say et al. | Jul 2009 | A1 |
| 20090187091 | Say et al. | Jul 2009 | A1 |
| 20090187092 | Say et al. | Jul 2009 | A1 |
| 20090187093 | Say et al. | Jul 2009 | A1 |
| 20090187094 | Say et al. | Jul 2009 | A1 |
| 20090187095 | Say et al. | Jul 2009 | A1 |
| 20090187381 | King et al. | Jul 2009 | A1 |
| 20090192351 | Nishino | Jul 2009 | A1 |
| 20090192368 | Say et al. | Jul 2009 | A1 |
| 20090192369 | Say et al. | Jul 2009 | A1 |
| 20090192370 | Say et al. | Jul 2009 | A1 |
| 20090192371 | Say et al. | Jul 2009 | A1 |
| 20090192372 | Say et al. | Jul 2009 | A1 |
| 20090192373 | Say et al. | Jul 2009 | A1 |
| 20090192374 | Say et al. | Jul 2009 | A1 |
| 20090192375 | Say et al. | Jul 2009 | A1 |
| 20090192376 | Say et al. | Jul 2009 | A1 |
| 20090192377 | Say et al. | Jul 2009 | A1 |
| 20090192378 | Say et al. | Jul 2009 | A1 |
| 20090192379 | Say et al. | Jul 2009 | A1 |
| 20090198115 | Say et al. | Aug 2009 | A1 |
| 20090198116 | Say et al. | Aug 2009 | A1 |
| 20090198175 | Say et al. | Aug 2009 | A1 |
| 20090203964 | Shimizu et al. | Aug 2009 | A1 |
| 20090203971 | Sciarappa | Aug 2009 | A1 |
| 20090203972 | Heneghan | Aug 2009 | A1 |
| 20090203978 | Say et al. | Aug 2009 | A1 |
| 20090204265 | Hackett | Aug 2009 | A1 |
| 20090210164 | Say et al. | Aug 2009 | A1 |
| 20090216101 | Say et al. | Aug 2009 | A1 |
| 20090216102 | Say et al. | Aug 2009 | A1 |
| 20090227204 | Robertson et al. | Sep 2009 | A1 |
| 20090227876 | Tran | Sep 2009 | A1 |
| 20090227940 | Say et al. | Sep 2009 | A1 |
| 20090227941 | Say et al. | Sep 2009 | A1 |
| 20090228214 | Say et al. | Sep 2009 | A1 |
| 20090231125 | Baldus | Sep 2009 | A1 |
| 20090234200 | Husheer | Sep 2009 | A1 |
| 20090243833 | Huang | Oct 2009 | A1 |
| 20090253960 | Takenaka et al. | Oct 2009 | A1 |
| 20090256702 | Robertson | Oct 2009 | A1 |
| 20090264714 | Chou | Oct 2009 | A1 |
| 20090264964 | Abrahamson | Oct 2009 | A1 |
| 20090265186 | Tarassenko et al. | Oct 2009 | A1 |
| 20090273467 | Elixmann | Nov 2009 | A1 |
| 20090277815 | Kohl et al. | Nov 2009 | A1 |
| 20090281539 | Selig | Nov 2009 | A1 |
| 20090292194 | Libbus et al. | Nov 2009 | A1 |
| 20090295548 | Ronkka | Dec 2009 | A1 |
| 20090296677 | Mahany | Dec 2009 | A1 |
| 20090301925 | Alloro et al. | Dec 2009 | A1 |
| 20090303920 | Mahany | Dec 2009 | A1 |
| 20090306633 | Trovato et al. | Dec 2009 | A1 |
| 20090312619 | Say et al. | Dec 2009 | A1 |
| 20090318303 | Delamarche et al. | Dec 2009 | A1 |
| 20090318761 | Rabinovitz | Dec 2009 | A1 |
| 20090318779 | Tran | Dec 2009 | A1 |
| 20090318783 | Rohde | Dec 2009 | A1 |
| 20090318793 | Datta | Dec 2009 | A1 |
| 20100006585 | Flowers et al. | Jan 2010 | A1 |
| 20100010330 | Rankers | Jan 2010 | A1 |
| 20100033324 | Shimizu et al. | Feb 2010 | A1 |
| 20100049006 | Magar | Feb 2010 | A1 |
| 20100049012 | Dijksman et al. | Feb 2010 | A1 |
| 20100049069 | Tarassenko et al. | Feb 2010 | A1 |
| 20100056878 | Partin | Mar 2010 | A1 |
| 20100056891 | Say et al. | Mar 2010 | A1 |
| 20100056939 | Tarassenko et al. | Mar 2010 | A1 |
| 20100057041 | Hayter | Mar 2010 | A1 |
| 20100062709 | Kato | Mar 2010 | A1 |
| 20100063438 | Bengtsson | Mar 2010 | A1 |
| 20100063841 | D'Ambrosia et al. | Mar 2010 | A1 |
| 20100069002 | Rong | Mar 2010 | A1 |
| 20100069717 | Hafezi et al. | Mar 2010 | A1 |
| 20100081894 | Zdeblick et al. | Apr 2010 | A1 |
| 20100099967 | Say et al. | Apr 2010 | A1 |
| 20100099968 | Say et al. | Apr 2010 | A1 |
| 20100099969 | Say et al. | Apr 2010 | A1 |
| 20100100077 | Rush | Apr 2010 | A1 |
| 20100100078 | Say et al. | Apr 2010 | A1 |
| 20100106001 | Say et al. | Apr 2010 | A1 |
| 20100118853 | Godfrey | May 2010 | A1 |
| 20100139672 | Kroll et al. | Jun 2010 | A1 |
| 20100168659 | Say et al. | Jul 2010 | A1 |
| 20100179398 | Say et al. | Jul 2010 | A1 |
| 20100185055 | Robertson | Jul 2010 | A1 |
| 20100191073 | Tarassenko et al. | Jul 2010 | A1 |
| 20100210299 | Gorbachov | Aug 2010 | A1 |
| 20100222652 | Cho | Sep 2010 | A1 |
| 20100228113 | Solosko | Sep 2010 | A1 |
| 20100233026 | Ismagliov et al. | Sep 2010 | A1 |
| 20100234706 | Gilland | Sep 2010 | A1 |
| 20100234715 | Shin | Sep 2010 | A1 |
| 20100234914 | Shen | Sep 2010 | A1 |
| 20100245091 | Singh | Sep 2010 | A1 |
| 20100249881 | Corndorf | Sep 2010 | A1 |
| 20100256461 | Mohamedali | Oct 2010 | A1 |
| 20100259543 | Tarassenko et al. | Oct 2010 | A1 |
| 20100268048 | Say et al. | Oct 2010 | A1 |
| 20100268049 | Say et al. | Oct 2010 | A1 |
| 20100268050 | Say et al. | Oct 2010 | A1 |
| 20100274111 | Say et al. | Oct 2010 | A1 |
| 20100280345 | Say et al. | Nov 2010 | A1 |
| 20100280346 | Say et al. | Nov 2010 | A1 |
| 20100298668 | Hafezi et al. | Nov 2010 | A1 |
| 20100298730 | Tarassenko et al. | Nov 2010 | A1 |
| 20100299155 | Findlay et al. | Nov 2010 | A1 |
| 20100312188 | Robertson et al. | Dec 2010 | A1 |
| 20100312580 | Tarassenko et al. | Dec 2010 | A1 |
| 20100332443 | Gartenberg | Dec 2010 | A1 |
| 20110004079 | Al Ali et al. | Jan 2011 | A1 |
| 20110009715 | O'Reilly et al. | Jan 2011 | A1 |
| 20110040203 | Savage et al. | Feb 2011 | A1 |
| 20110050431 | Hood et al. | Mar 2011 | A1 |
| 20110054265 | Hafezi et al. | Mar 2011 | A1 |
| 20110065983 | Hafezi et al. | Mar 2011 | A1 |
| 20110081860 | Brown et al. | Apr 2011 | A1 |
| 20110105864 | Robertson et al. | May 2011 | A1 |
| 20110144470 | Mazar et al. | Jun 2011 | A1 |
| 20110237924 | McGusty et al. | Sep 2011 | A1 |
| 20110279963 | Kumar et al. | Nov 2011 | A1 |
| 20120024889 | Robertson et al. | Feb 2012 | A1 |
| 20120029309 | Paquet et al. | Feb 2012 | A1 |
| 20120083715 | Yuen et al. | Apr 2012 | A1 |
| 20120101396 | Solosko et al. | Apr 2012 | A1 |
| 20120197144 | Christ et al. | Aug 2012 | A1 |
| 20120214140 | Brynelsen et al. | Aug 2012 | A1 |
| 20120265544 | Hwang et al. | Oct 2012 | A1 |
| 20120299723 | Hafezi et al. | Nov 2012 | A1 |
| 20120310070 | Kumar et al. | Dec 2012 | A1 |
| 20120316413 | Liu et al. | Dec 2012 | A1 |
| 20130030259 | Thomsen et al. | Jan 2013 | A1 |
| 20130057385 | Murakami et al. | Mar 2013 | A1 |
| 20130060115 | Gehman et al. | Mar 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 1991868 | Jul 2007 | CN |
| 101005470 | Jul 2007 | CN |
| 201076456 | Jun 2008 | CN |
| 0344939 | Dec 1989 | EP |
| 1246356 | Oct 2002 | EP |
| 1534054 | May 2005 | EP |
| 1702553 | Sep 2006 | EP |
| 1789128 | May 2007 | EP |
| 2143369 | Jan 2010 | EP |
| 2432862 | Jun 2007 | GB |
| 172917 | Jun 2010 | IL |
| 61017949 | Jan 1986 | JP |
| 61072712 | Apr 1986 | JP |
| 05-228128 | Sep 1993 | JP |
| 10-14898 | Jan 1998 | JP |
| 2000-506410 | May 2000 | JP |
| 2002-224053 | Aug 2002 | JP |
| 2002263185 | Sep 2002 | JP |
| 2002291684 | Oct 2002 | JP |
| 2004-7187 | Jan 2004 | JP |
| 2004134384 | Apr 2004 | JP |
| 2004-313242 | Nov 2004 | JP |
| 2005-073886 | Mar 2005 | JP |
| 2005-304880 | Apr 2005 | JP |
| 2005124708 | May 2005 | JP |
| 2005-532841 | Nov 2005 | JP |
| 2005-532849 | Nov 2005 | JP |
| 2006006377 | Jan 2006 | JP |
| 2006509574 | Mar 2006 | JP |
| 2006-177699 | Jul 2006 | JP |
| 2006-187611 | Jul 2006 | JP |
| 2006278091 | Oct 2006 | JP |
| 2006346000 | Dec 2006 | JP |
| 2007-313340 | Dec 2007 | JP |
| 2008011865 | Jan 2008 | JP |
| 2009-061236 | Mar 2009 | JP |
| 20020015907 | Mar 2002 | KR |
| 20020061744 | Jul 2002 | KR |
| 200609977523 | Jul 2006 | KR |
| 927471 | Nov 2009 | KR |
| 10-2012-09995 | Sep 2012 | KR |
| 553735 | Sep 2003 | TW |
| 200724094 | Jul 2007 | TW |
| 8802237 | Apr 1988 | WO |
| WO8802237 | Apr 1988 | WO |
| WO8802237 | Apr 1988 | WO |
| WO9308734 | May 1993 | WO |
| WO9319667 | Oct 1993 | WO |
| WO9401165 | Jan 1994 | WO |
| WO9714112 | Apr 1997 | WO |
| WO9739963 | Oct 1997 | WO |
| WO9843537 | Oct 1998 | WO |
| WO9937290 | Jul 1999 | WO |
| WO9959465 | Nov 1999 | WO |
| WO0033246 | Jun 2000 | WO |
| WO0100085 | Jan 2001 | WO |
| 0147466 | Jul 2001 | WO |
| WO0149364 | Jul 2001 | WO |
| WO0174011 | Oct 2001 | WO |
| WO0180731 | Nov 2001 | WO |
| WO0245489 | Jun 2002 | WO |
| WO02058330 | Jul 2002 | WO |
| WO02062276 | Aug 2002 | WO |
| WO02087681 | Nov 2002 | WO |
| WO02095351 | Nov 2002 | WO |
| WO03005877 | Jan 2003 | WO |
| WO03050643 | Jun 2003 | WO |
| WO2004014225 | Feb 2004 | WO |
| WO2004039256 | May 2004 | WO |
| WO2004059551 | Jul 2004 | WO |
| WO2004066834 | Aug 2004 | WO |
| WO2004066903 | Aug 2004 | WO |
| WO2004068748 | Aug 2004 | WO |
| WO2004068881 | Aug 2004 | WO |
| WO2004075751 | Sep 2004 | WO |
| WO2004109316 | Dec 2004 | WO |
| WO2005011237 | Feb 2005 | WO |
| 2005020023 | Mar 2005 | WO |
| WO2005024687 | Mar 2005 | WO |
| WO2005041767 | May 2005 | WO |
| WO2005047837 | May 2005 | WO |
| WO2005051166 | Jun 2005 | WO |
| WO2005053517 | Jun 2005 | WO |
| WO2005082436 | Sep 2005 | WO |
| WO2005083621 | Sep 2005 | WO |
| WO2005110238 | Nov 2005 | WO |
| WO2006021932 | Mar 2006 | WO |
| WO2006027586 | Mar 2006 | WO |
| WO2006028347 | Mar 2006 | WO |
| WO2006035351 | Apr 2006 | WO |
| 2006055892 | May 2006 | WO |
| 2006055956 | May 2006 | WO |
| WO2006046648 | May 2006 | WO |
| WO2006075016 | Jul 2006 | WO |
| WO2006100620 | Sep 2006 | WO |
| 2006104843 | Oct 2006 | WO |
| WO2006109072 | Oct 2006 | WO |
| 2006116718 | Nov 2006 | WO |
| 2006127355 | Nov 2006 | WO |
| WO 2006116718 | Nov 2006 | WO |
| WO2006119345 | Nov 2006 | WO |
| 2007001724 | Jan 2007 | WO |
| 2007001742 | Jan 2007 | WO |
| 2007013952 | Feb 2007 | WO |
| 2007014084 | Feb 2007 | WO |
| 2007021496 | Feb 2007 | WO |
| WO2007014527 | Feb 2007 | WO |
| 2007027660 | Mar 2007 | WO |
| 2007028035 | Mar 2007 | WO |
| WO2007028035 | Mar 2007 | WO |
| 2007036741 | Apr 2007 | WO |
| 2007036746 | Apr 2007 | WO |
| WO2007036687 | Apr 2007 | WO |
| WO2007036741 | Apr 2007 | WO |
| WO2007036746 | Apr 2007 | WO |
| WO2007040878 | Apr 2007 | WO |
| WO2007067054 | Jun 2007 | WO |
| WO2007071180 | Jun 2007 | WO |
| WO2007096810 | Aug 2007 | WO |
| WO2007101141 | Sep 2007 | WO |
| WO2007115087 | Oct 2007 | WO |
| WO2007120946 | Oct 2007 | WO |
| 2007130491 | Nov 2007 | WO |
| WO2007127316 | Nov 2007 | WO |
| WO2007127879 | Nov 2007 | WO |
| WO2007127945 | Nov 2007 | WO |
| WO2007128165 | Nov 2007 | WO |
| WO2007133526 | Nov 2007 | WO |
| 2007149546 | Dec 2007 | WO |
| WO2007143535 | Dec 2007 | WO |
| 2008008281 | Jan 2008 | WO |
| WO2008030482 | Mar 2008 | WO |
| 2008052136 | May 2008 | WO |
| 2008063626 | May 2008 | WO |
| WO2008061138 | May 2008 | WO |
| 2008066617 | Jun 2008 | WO |
| WO2008076464 | Jun 2008 | WO |
| WO2008089232 | Jul 2008 | WO |
| WO2008091683 | Jul 2008 | WO |
| 2008095183 | Aug 2008 | WO |
| 2008101107 | Aug 2008 | WO |
| WO2008097652 | Aug 2008 | WO |
| 2008112577 | Sep 2008 | WO |
| 2008112578 | Sep 2008 | WO |
| 2008120156 | Oct 2008 | WO |
| WO2008133394 | Nov 2008 | WO |
| WO2008134185 | Nov 2008 | WO |
| 2009001108 | Dec 2008 | WO |
| WO2008150633 | Dec 2008 | WO |
| WO2009001108 | Dec 2008 | WO |
| WO2009006615 | Jan 2009 | WO |
| WO2009029453 | Mar 2009 | WO |
| WO2009036334 | Mar 2009 | WO |
| WO2009051829 | Apr 2009 | WO |
| WO2009051830 | Apr 2009 | WO |
| WO2009063377 | May 2009 | WO |
| WO2009081348 | Jul 2009 | WO |
| WO2009111664 | Sep 2009 | WO |
| WO2009146082 | Dec 2009 | WO |
| WO2010000085 | Jan 2010 | WO |
| WO2010009100 | Jan 2010 | WO |
| WO2010011833 | Jan 2010 | WO |
| 2010019778 | Feb 2010 | WO |
| 2010057049 | May 2010 | WO |
| WO2010075115 | Jul 2010 | WO |
| WO2010080765 | Jul 2010 | WO |
| WO2010080843 | Jul 2010 | WO |
| WO2010107563 | Sep 2010 | WO |
| WO2010132331 | Nov 2010 | WO |
| WO2010135516 | Nov 2010 | WO |
| WO2011068963 | Jun 2011 | WO |
| WO2011133799 | Oct 2011 | WO |
| WO2011159336 | Dec 2011 | WO |
| WO2011159337 | Dec 2011 | WO |
| WO2011159338 | Dec 2011 | WO |
| WO2011159339 | Dec 2011 | WO |
| WO2012104657 | Aug 2012 | WO |
| WO2012158190 | Nov 2012 | WO |
| WO2013012869 | Jan 2013 | WO |
| Entry |
|---|
| Bohidar et al., “Dielectric Behavior of Gelatin Solutions and Gels” Colloid Polym Sci (1998) 276:81-86. |
| Dhar et al., “Electroless nickel plated contacts on porous silicon” Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996). |
| Eldek A., “Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications” Progress in Electromagnetics Research PIER 59, 1-15 (2006). |
| Fawaz et al., “Enhanced Telemetry System using CP-QPSK Band-Pass Modulation Technique Suitable for Smart Pill Medical Application” IFIP IEEE Dubai Conference (2008); http://www.asic.fh-offenburg.de/downloads/ePille/IFIP—IEEE—Dubai—Conference.pdf. |
| Ferguson et al., “Dialectric Constant Studies III Aqueous Gelatin Solutions” J. Chem. Phys. 2, 94 (1934) p. 94-98. |
| Furse C. M., “Dipole Antennas” J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581. |
| Given Imaging, “Agile Patency Brochure” (2006) http://www.inclino.no/documents/AgilePatencyBrochure—Global—GMB-0118-01.pdf; 4pp. |
| ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 4pp. |
| Intromedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (http://www.intromedic.com/en/product/productinfo.asp). |
| Kamada K., “Electrophoretic deposition assisted by soluble anode” Materials Letters 57 (2003) 2348-2351. |
| NPL—AntennaBasics.pdf, Radio Antennae, http://www.erikdeman.de/html/sail018h.htm; (2008) 3pp. |
| O'Brien et al., “The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering” Surface and Coatings Technology (1996) 86-87; 200-206. |
| Roulstone, et al., “Studies on Polymer Latex Films: I. A study of latex film morphology” Polymer International 24 (1991) pp. 87-94. |
| Shin et al., “A Simple Route to Metal Nanodots and Nanoporous Metal Films”; Nano Letters, vol. 2, No. 9 (2002) pp. 933-936. |
| Shrivas et al., “A New Platform for Bioelectronics-Electronic Pill”, Cummins College, (2010).; http://www.cumminscollege.org/downloads/electronics—and—telecommunication/Newsletters/Current%20Newsletters.pdf; First cited in third party client search conducted by Patent Eagle Search May 18, 2010. |
| “The SmartPill Wireless Motility Capsule” Smartpill, The Measure of GI Health; (2010) http://www.smartpillcorp.com/index.cfm?pagepath=Products/The—SmartPill—Capsule&id=17814. |
| Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346 (2007). |
| U.S. Appl. No. 12/238,345, filed Sep. 25, 2008, Hooman et al., Non-Final Office Action mailed Jun. 13, 2011 22pp. |
| Walkey, “MOSFET Structure and Processing”; 97.398* Physical Electronics Lecture 20; Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 24 pp. |
| Wongmanerod et al., “Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry” Applied Surface Science 172 (2001) 117-125. |
| Heydari et al., “Analysis of the PLL jitter due to power/ground and substrate noise”; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16. |
| Philips Respironics (http/minimitter.com/products.cfm) Products, Noninvasive Technology to Help Your Studies Succeed. 510(k) Permanent Notification for Vital Sense. Apr. 22, 2004. |
| Sanduleanu et al., “Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers” (2002) IEEE MTT-S International Microwave Symposium Digest 545-8. |
| Tajalli et al., “Improving the power-delay performance in subthreshold source-coupled logic circuits” Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation, Springer Berlin Heidelberg (2008) 21-30. |
| Yang et al., “Fast-switching frequency synthesizer with a discriminator-aided phase detector” IEEE Journal of Solid-State Circuits (2000) 35(10): 1445-52. |
| “Smartlife awarded patent for knitted transducer” Innovation in Textiles News: http://www.innovationintextiles.com/articles/208.php; 2pp. (2009). |
| Coury, L. “Conductance Measurement Part 1: Theory”; Current Separations, 18:3 (1999) p. 91-96. |
| Watson, et al., “Determination of the relationship between the pH and conductivity of gastric juice” Physiol Meas. 17 (1996) pp. 21-27. |
| Gaglani S. “Put Your Phone, or Skin, on Vibrate” MedGadget; Mar. (2012) http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html 8pp. |
| Halthion Medical Technologies “Providing Ambulatory Medical Devices Which Monitor, Measure and Record” webpage. Online website: http://www.halthion.com/; downloaded May 30, 2012. |
| Jimbo et al., “Gastric-fluid-utilized micro battery for micro medical devices” The Sixth International Workshop on Micro and Nanotechnology for Power Geneartion and Energy Conservation Applications, (2006) pp. 97-100. |
| Jung, S. “Dissolvable ‘Transient Electronics’ Will Be Good for Your Body and the Environment” MedGadget; Oct. 1, 2012; Onlne website: http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html; downloaded Oct. 24, 2012; 4 pp. |
| Owano, N., “Study proposes smart sutures with sensors for wounds” Phys.org. Aug. 2012. http://phys.org/news/2012-08-smart-sutures-sensors-wounds.html. |
| Platt, D., “Modulation and Deviation” AE6EO, Foothills Amateur Radio Society; Oct. 26, 2007; 61 pp. |
| Rolison et al., “Electrically conductive oxide aerogels: new materials in electrochemistry” J. Mater. Chem. (2001) 1, 963-980. |
| “PALO Bluetooth Baseband” PALO Bluetooth Resource Center (2002) Retrieved from Internet Dec. 12, 2012 at URL: http://palowireless.com/bluearticles/baseband.asp; first cited in Office Action dated Jan. 17, 2013 for EP08853901.0. |
| Trutag, Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; “Product Authentication and Brand Protection Solutions”; http://www.trutags.com/; downloaded Feb. 12, 2013; 1 pp. |
| Lin et al., “Do Physiological Data Relate to Traditional Usability Indexes?” Proceedings of OZCHI 2005, Canberra, Australia (2005) 10 pp. |
| Mandryk et al., “A physiological approach for continuously modeling user emotion in interactive play environments” Proceedings of Measuring Behavior (2008) (Maastrichtm The Netherlandsm Aug. 26-29) 2 pp. |
| Mandryk et al., “Objectively Evaluating Entertainment Technology” Simon Fraser University; CHI (2004) ACM 1-58113-703-6/04/0004; 2 pp. |
| Baskiyar, S. “A Real-time Fault Tolerant Intra-body Network” Dept. of Comp. Sci & Soft Eng; Auburn University; Proceedings of the 27th Annual IEEE Conference; 0742-1303102 (2002) IEEE; 6 pp. |
| Evanczuk, S., “PIC MCU software library uses human body for secure communications link” EDN Network; edn.com; Feb. 26, 2013 Retrieved from internet Jun. 19, 2013 at http://www.edn.com/electronics-products/other/4407842/PIC-MCU-software-library-uses-human-body-for-secure-communications-link; 5 pp. |
| Hotz “The Really Smart Phone” The Wall Street Journal, What They Know (2011); 6 pp.; http://online.wsj.com/article/SB10001424052748704547604576263261679848814.html?mod=djemTECH—t. |
| Winter, J. et al. “The material properties of gelatin gels”; USA Ballistic Research Laboratories, Mar. 1975, p. 1-157. |
| Kim et al., “A Semi-Interpenetrating Network System for a Polymer Membrane”; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997). |
| Gilson, D.R. “Molecular dynamics simulation of dipole interactions”, Department of Physics, Hull University, Dec. 2002, p. 1-43. |
| Li, P-Y, et al. “An electrochemical intraocular drug delivery device”, Sensors and Actuators A 143 (2008) p. 41-48. |
| NPL—AntennaBasics.pdf, p. 1-3. |
| Santini, J.T. et al, “Microchips as controlled drug delivery-devices”, Agnew. Chem. Int. Ed. 2000, vol. 39, p. 2396-2407. |
| Shawgo, R.S. et al. “BioMEMS from drug delivery”, Current Opinion in Solid State and Material Science 6 (2002), p. 329-334. |
| Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346. |
| Tierney, M.J. et al “Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules”, J. Electrochem. Soc., vol. 137, No. 6, Jun. 1990, p. 2005-2006. |
| Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med (2007) vol. 1, No. 1, Issue 1, pp. 35 of 46. |
| “ASGE Technology Status Evaluation Report: wireless capsule endoscopy” American Soc. For Gastrointestinal Endoscopy (2006) vol. 63, No. 4; 7 pp. |
| Aydin et al., “Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems” Sch. of Eng. & Electron., Edinburgh Univ., UK; (2003); abstract. |
| Brock, “Smart Medicine: The Application of Auto-ID Technology to Healthcare” Auto-ID Labs (2002) http://www.autoidlabs.org/uploads/media/MIT-AUTOID-WH-010.pdf. |
| Delvaux et al., “Capsule endoscopy: Technique and indications” Clinical Gastoenterology (2008) vol. 22, Issue 5, pp. 813-837. |
| Fawaz et al., “Enhanced Telemetry System using CP-QPSK Band-Pass Modulation Technique Suitable for Smart Pill Medical Application” IFIP IEEE Dubai Conference (N.D.); http://www.asic.fh-offenburg.de/downloads/ePille/IFIP—IEEE—Dubai Conference.pdf. |
| Given Imaging, “Agile Patency Brochure” http://www.inclino.no/documents/AgilePatencyBrochure—Global—GMB-0118-01.pdf;(N.D.) 4pp. |
| Gonzalez-Guillaumin et al., “Ingestible capsule for impedance and pH monitoring in the esophagus” IEEE Trans Biomed Eng. (2007) 54(12: 2231-6; abstract. |
| Greene, “Edible RFID microchip monitor can tell if you take your medicine” Bloomberg Businessweek (2010) 2 pp.; http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html. |
| Melanson, “Walkers swallow RFID pills for science” Engadget (2008); http://www.engadget.com/2008/07/29/walkers-swallow-rfid-pills-for-science/. |
| “New ‘smart pill’ to track adherence” E-Health-Insider (2010) http://www.e-health-insider.com/news/5910/new—‘smart—pill’—monitors—medicines. |
| “RFID “pill” monitors marchers” RFID News (2008) http://www.rfidnews.org/2008/07/23/rfid-pill-monitors-marchers/. |
| “SensiVida minimally invasive clinical systems” Investor Presentation Oct. 2009 28pp; http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf. |
| Shrivas et al., “A New Platform for Bioelectronics-Electronic Pill”, Cummins College, N.D.; http://www.cumminscollege.org/downloads/electronics—and—telecommunication/Newsletters/Current%20Newsletters.pdf. |
| “The SmartPill Wireless Motility Capsule” Smartpill, The Measure of GI Health; http://www.smartpillcorp.com/index.cfm?pagepath=Products/The—SmartPill—Capsule &id=17814. |
| Solanas et al., “RFID Technology for the Health Care Sector” Recent Patents on Electrical Engineering (2008) 1, 22-31. |
| Swedberg, “University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials” RFID Journal (2010) Apr. 27th; http://www.rfidjournal.com/article/view/7560/1. |
| University of Florida News “Rx for health: Engineers design pill that signals it has been swallowed” (2010) 2pp.; http://news.ufl.edu/2010/03/31/antenna-pill-2/. |
| ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. pp. 1-4. |
| Walkey, “MOSFET Struture and Processing”; 97.398* Physical Electronics Lecture 20; pp. 1-24. |
| Mackay et al., Radio telemetering from within the body: Inside information is revealed by tiny transmitters that can be swallowed or implanted in man or animal. Science 1961;134(3486):1196-1202. |
| Mackay et al., Endoradiosonde, Nature 1957;179(4572):1239-40, 179. |
| Zworkin, A ‘radio pill.’ Nature 1957;179:898. |
| Yao et al., Low Power Digital Communication in Implantable Devices Using Volume Conduction of Biological Tissues. Proceedings of the 28th IEEE, EMBC Annual International Conference 2006 (Aug. 30-Sep. 3); New York, USA. |
| McKenzie et al., Validation of a new telemetric core temperature monitor. J. Therm. Biol. 2004;29(7-8):605-11. |
| Tatbul et al., Confidence-based data management for personal area sensor networks. ACM International Conference Proceeding Series 2004;72. |
| Zimmerman, Personal Area Networks:Near-field intrabody communication. IBM Systems Journal 1996;35(3-4):609-17. |
| Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. Sep. 21, 1999. |
| Mini Mitter Co, Inc. 510(k) Premarket Notification for VitalSense. Apr. 22, 2004. |
| Mini Mitter Co, Inc. Actiheart. Traditional 510(k) Summary. Sep. 27, 2005. |
| Mini Mitter Co, Inc. VitalSense Integrated Physiological Monitoring System. Product Description. |
| Mini Mitter Co, Inc. VitalSense—Wireless Vital Signs Monitoring. Temperatures.com Mar. 31, 2009. |
| Mini Mitter Co, Inc. Noninvasive technology to help your studies succeed. Mini Mitter.com Mar. 31, 2009. |
| Barrie, Heidelberg pH capsule gastric analysis. Textbook of Natural Medicine, 1992, Pizzorno, Murray & Barrie. |
| Carlson et al., Evaluation of a non-invasive respiratory monitoring system for sleeping subjects, Physiological Measurement 1999;20(1):53. |
| Mojaverian et al., Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology 1985;89(2):392-7. |
| Xiaoming et al., A telemedicine system for wireless home healthcare based on bluetooth and the internet. Telemedicine Journal and e-health 2004;10(S2):S110-6. |
| Intromedic, MiroCam Innovative Capsule Endoscope Pamphlet. 8 pages. (http://www.intromedic.com/en/productinfo.asp). |
| Number | Date | Country | |
|---|---|---|---|
| 20100022836 A1 | Jan 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60894171 | Mar 2007 | US | |
| 60915635 | May 2007 | US |
